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Theses Abstract 
Background: Lung function assessments have become the cornerstone of 
understanding the ever-increasing burden of non-communicable respiratory conditions 
worldwide. The introduction of pulmonary function testing (PFT) has made maximal 
expiratory ﬂow/volume (MEFV) measurements the basis of lung function assessments 
and spirometry the most widely used diagnostic tool for lung function testing. The 
effectiveness of spirometry to distinguish between normal and abnormal lung function 
has been realised in adults; however, there is an observed history of misinterpretation in 
children. The quality of measurements remains a major concern in children and good 
quality measurements are critical in the diagnosis of any health condition as well as 
understanding the burden of abnormal lung function in children in low and middle-
income countries (LMICs). 
Objective: This study describes the quality and variation of spirometry reads for 
evaluating lung function in children in a Malawian population. 
Methods: This study was conducted according to a protocol developed and granted 
ethical approval by the Faculty of Health Sciences Human Research Ethics Committee, 
University of Cape Town (HREC REF 669/2018). The protocol describes the parent 
study data collection, project analysis plans and ethical and other considerations. 
Current literature on lung function using spirometry was systematically reviewed and 
synthesised. The literature review included primary studies and review articles that 
included spirometry measurement in children from settings in Africa and other low- and 
middle- income countries. The descriptive study involves secondary analysis of data 
contributed by the Children Lung Health study, a cross-sectional survey conducted in 
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Malawi. Spirometry measurements from 802 healthy children aged 6-8 years, 
inexperienced in performing MEFV manoeuvres, are evaluated. Data in the primary 
study were collected by means of a structured questionnaire which included items on 
socio-demographic characteristics and spirometry was performed according to the 
American Thoracic Society and European Respiratory Society (ATS/ERS) guidelines 
using an Easy on-PC spirometer in the participant‘s home. The ATS/ERS standards for 
adults and the modified recommendations for children were applied to evaluate quality. 
Descriptive statistics were used to describe the quality of spirometry indices and 
univariable logistic regression to identify and describe variables that are predictors of 
quality.  
Results: The findings of the study were that many children (34%) failed to reach the 
complete ATS/ERS quality standards. The end-of-test criteria (forced expiratory time) 
was the most difficult to meet for children and if this is not met (i.e. exhalation is not 
complete), the forced vital capacity (FVC) will be underestimated leading to it being 
misinterpreted. More than 30% of the children failed to meet the repeatability criteria 
when the relative differences for FVC and forced expiratory volume in the first second 
(FEV1) was used, yet they are the most appropriate in paediatric practice as compared 
to absolute differences. Young children were more likely to produce poor quality 
spirometry as compared to older children. 
Conclusion: Young children may perform acceptable spirometry according to the 
modified ATS/ERS recommendations; however, the quality remains suboptimal. Further 
modification of the already lowered quality standards, seems to be the viable option, but 
the implications of this clinically has not been evaluated. Other alternatives need to be 
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explored for this group. 
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Background  
Non-communicable diseases (NCDs) are a growing public health concern globally due 
to a rapidly increasing burden which may soon overtake the burden of infectious 
diseases (Global Health Estimates, 2016 and GBD, 2013). Chronic lung diseases such 
as COPD and asthma are one of the major contributors to the burden of NCDs in sub-
Saharan Africa (Ahmed, Robinson and Mortimer, 2017). African countries, like many 
other low and middle-income countries (LMIC), are likely to be significantly affected by 
chronic lung diseases due to prevailing conditions favouring disease in these settings 
such as high rates of tuberculosis and biomass fuel use  (Sana et al, 2018). 
However, the limited data available in published literature for Africa (Finney et al, 2013) 
limits the knowledge about the status quo of chronic lung disease in the continent. Most 
work assumes a high prevalence of respiratory disease due to the degree of exposure 
and risk in these areas, for example, due to biomass fuel dependence and high HIV/TB 
prevalence (Meghji et al, 2016). The burden of chronic lung disease is often measured 
by self-reported correlates of compromised lung function (e.g. breathlessness) or by 
clinical measurement. The most common clinical measure of lung function is by 
spirometry (Miller et al, 2005).  
Spirometry is a non-invasive evaluation of lung function. A spirometry evaluation 
involves the participant inhaling and exhaling into a device (spirometer), which 
measures lung volumes. Low lung volume may be due to reduced vital capacity where a 
participant, although having achieved maximal inhalation, the amount of air blown out is 
reduced (Rylance, 2018). This means that participants may have started off with full 
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lungs, however their lungs could be smaller than average causing a condition called 
restriction or restrictive lung disease (Miller et al, 2005). On the other hand, the air 
passages on the lungs could also be narrowed leading to a reduced early expiration or 
a situation where a participant may take longer than normal to fully exhale. This is 
referred to as obstruction or obstructive lung disease. The measure of the lungs to 
inspire to full capacity and forcefully expire at a given point in time can be used to score 
or rank individuals into different lung function categories e.g. normal or obstructed. The 
use of spirometry to measure lung volumes over time can be converted into a measure 
of abnormal lung function, which can then be used to estimate burden.  
Measuring lung function is fundamental in understanding the burden of chronic lung 
disease in African populations. Recent studies measuring lung function by spirometry 
have found a substantial burden of abnormal lung function, especially restriction, in sub-
Saharan populations (Meghji et al, 2016) and lower than expected forced vital capacity 
(FVC) (Obaseki et al, 2017). However, the scarcity of data is to likely provide inaccurate 
estimates (either over or underestimation) of the extent of disease and the amount of 
long term damage caused by chronic lung disease (Ahmed, Robinson and Mortimer, 
2017). Although progress is being made, the diagnosis of lung function abnormalities is 
poor when compared to other NCDs, yet it is essential in informing decision making for 
disease management and planning of health services.  
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The most important estimates of lung function measured by spirometry are FVC (Figure 
1 B) and FEV1. FVC measures the amount of air starting from the point of full inhalation 
to the end of a forceful expiration, which is as complete as possible. The first second of 
the FVC manoeuvre is the FEV1 (Miller et al, 2005). Together these estimates are used 
to calculate a FEV1/FVC ratio which gives insight into the clinical disorders commonly 
termed obstruction and restriction. Because height, age, and weight are known to 
directly affect lung volumes, FVC and FEV1 are usually represented as standardized z-
scores. Although the spirometer provides other measurements, they are rarely 
interpreted or analysed in clinical studies, but they can be used for quality control.  
Additional measures available include back extrapolated volume (BEV) and end of test 
volume (EOTV). These two measures are utilized to classify a spirometry manoeuvre as 
―acceptable‖ or not. There are few epidemiological studies in the literature that 
A .                                                                                                                                     B. 
Figure 1 A & B Standard traces showing how to read off residual volume, tidal volume, 
expiratory reserve volume, inspiratory reserve volume, vital capacity and total lung capacity. 
(Source: Nuffield foundation, 2011, used with by permission). 
i.e. FVC 
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investigate the association of BEV and EOTV with other measures of lung function, or 
the association between BEV/EOTV with FVC and FEV1. Another spirometry outcome 
of interest is the forced expiratory time (FET) which accounts for the minimal expiratory 
time which is normally less for children when compared to adults. 
In general, a good diagnostic test is characterized by high specificity and sensitivity, 
which for this procedure is known to depend both on the individual being tested and 
upon the manufacturers and technicians using this instrument (Miller et al, 2005). The 
quality of spirometry measurements is of paramount importance in correctly diagnosing 
poor lung function. Poor quality BEV and EOTV renders a manoeuvre unacceptable for 
a FVC and FEV1 measurement. The BEV can be used to identify individuals who do not 
start off with a forceful exhalation, whilst the EOTV identifies those individuals who have 
not completely exhaled (Miller et al, 2005).  
Using poor-quality manoeuvres may lead to incorrect diagnosis and lowers the 
sensitivity and specificity of spirometry as a diagnostic tool. Though there is evidence 
that the quality of spirometry varies within and between manoeuvres as well individuals 
(Meghji et al, 2016), the possible associations between poor quality spirometry and poor 
lung health have not been well described. Available literature shows evidence that 
suggests a relationship between poor quality spirometry and poor lung function (Enright 
et al, 2011), but information is limited.  Individual characteristics that have been found to 
be associated with spirometry abnormalities include sex, age, BMI, education, smoking, 
occupation, biomass exposure, TB/HIV status, and various blood-based biomarkers 
(Meghji et al, 2017). These factors have been identified as independent predictors of the 
quality of spirometry, in meeting the requirements by the ATS/ERS 2005 spirometry 
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standards (Enright et al, 2011). 
Classification of spirometry measures into clinically meaningful diagnosis e.g. restrictive 
disease relies on the use of reference values. Reference values are a range of normal 
values for populations used to base lung function measurements and these vary 
between populations and countries (Miller et al, 2005).  The variability in normal values, 
and the use of reference values themselves, impacts the reliability of test results, 
particularly when reducing spirometry measurements to a binary classification.  
There are varying perspectives on the use of spirometry reference values, and the 
definition of normal values for healthy lung function, specifically around the use of 
different normal values for different populations. The American Thoracic Society (ATS) 
and the European Respiratory Society (ERS) recommended that reference range 
development be drawn and based on populations being studied i.e. samples with similar 
ethnicity/race (Kiefer et al, 2016).  
This study seeks to describe the variation in the quality of spirometry reads when 
measuring lung function in typical LMIC settings. It will contribute knowledge on 
suboptimal spirometry and the description of the variation in the sub Saharan Africa 
study population. This will highlight the difficulty in measuring lung function especially 
when children with poor lung function cannot produce good quality traces (Rylance, 
2017).  
Findings of this study will provide a broad understanding of how poor-quality traces are 
associated with each other or other variables existing in the population that influence 
spirometry reads. This study will also contribute to the discussion of the utility of sub-
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quality spirometry clinically and its effects in achieving acceptable measurements for 
lung function diagnosis.  Understanding of the variations, patterns and association will 
inform decision making on prevention and control measures. 
 
2. Study aims and objectives 
The objective of the study is to describe the quality and variation of spirometry reads for 
evaluating lung function in children in a Malawian population. 
Objectives 
1. Describe the quality of spirometry and estimate the frequency of poor quality 
traces in children using BEV and EOTV measurement criteria for manoeuvre 
acceptability in children 
2. Assess the interpretive changes of BEV and EOTV when the quality rules are 
relaxed or made more stringent 
3. Compare spirometry quality across selected variables such as age, sex, height, 
weight, size of lung, effort/strength of person, personal characteristics/underlying 
clinical conditions in the quality of traces in children aged 6-8 years. 
4. Compare observed quality with published guidelines for spirometry quality 
assessment 
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3. Study design 
This descriptive study involved secondary data analysis from contributed data that has 
been de-identified and anonymized at source.  
The following is a brief description of the original study design. The data originated from 
the Children Lung Health study (CLHS), a cross-sectional survey, conducted in Malawi. 
The CLHS is titled ―Child lung health and exposure to household air pollution in rural 
Malawi” and was approved by the College of Medicine Research Ethics Committee 
(COMREC) p.07/16/1994 in Malawi and LSTM Research Ethics Committee (REC) 16-
040. This study protocol sought ethical approval from the Faculty of Health Sciences 
Human Research Ethics Committee, University of Cape Town. 
All data was anonymized and could not be traced to the original participants. Data had 
already been collected and analysed except with regards to the variables this study 
seeks to focus on. This study describes the use of spirometry as a reference standard 
for testing lung function and clinical diagnosis in children. Spirometry reads were 
analysed to evaluate its quality and variations in the sub-Saharan Africa population with 
focus on BEV and EOTV as well as the quality control (QC) criterion which uses the 
difference between FEV1 or FVC between traces as percentage for children. 
4. Characteristics of study population 
Data was already extracted and de-identified. It included measures from the following 
groups:  
The CLHS study was conducted among the same Chikwawa communities that 
participated in Cooking and Pneumonia Study (CAPS). Children who were included in 
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the CLHS were from households that had participated in the Cooking and Pneumonia 
Study (CAPS) especially the ALHS and Carbon monoxide exposure sub-studies. 
Assenting children were recruited from each of the 50 village level clusters in 
Chikwawa, in households with at least one child aged 6-8 years. 
Exclusion criteria: Children were excluded if they were currently on treatment for 
tuberculosis or if they currently suffer from acute respiratory infection (cough < 1week, 
with fever +/- increased work of breathing) and or show a contraindication to spirometry 
(chest or abdominal pain, haemoptysis). 
Sample size 
Datasets of children that participated in the CLHS was purposively used. All individuals 
had performed spirometry for lung function measurements in the study. The CLHS 
recruited 802 children between 6-8 years of age. The sample size was determined to 
allow estimates of non-communicable lung disease with a precision (95% CI) of ±2.6 to 
±3.8% and a prevalence of 10-25% was assumed (Rylance et al, 2017). Study sample 
provided sufficient power (>80%) to estimate moderate to large associations under 
multivariable regression models. Below is the calculation for sample size: 
2
2
(1 )p p z
n
d


 
p is the anticipated population proportion, d is the precision required on either side of 
the proportion and z  = 1.96.  
the Anticipated population proportion (p) was 25%; for the 95% CI: z = 1.96) and 
Desired precision (d) was 3.85% 
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n = (0.25(1-0.25)1.96^2)/0.038 = 499 children were required for the study to achieve at 
least 80% power. 
Research procedures and data collection methods 
Research Procedures 
Secondary data analysis was done by the researcher from datasets already collected by 
the CLHS in Malawi. Data was provided in de-identified, anonymized digital format. 
Researchers carried out data cleaning, data manipulation and data analysis to answer 
the question of this study, described in analysis methods below. 
Data Collection Methods 
This study used secondary data that was already collected. The following procedures 
were followed when collecting data in the study being used: 
The CLHS study collected data on children during home visits after consent was given. 
A questionnaire was also administered in Chichewa or English by study staff and it 
included questions from the international study of asthma and allergies in children 
(ISAAC) and burden of lung disease (BOLD) studies (Asher et al, 1995 and Buist et al, 
2005). Questions asked were related to the frequency of symptoms such as 
breathlessness, cough, asthma, phlegm, eczema rhinitis, and for detailed information 
about hospital admissions, HIV/TB diagnoses, and any treatments received. 
Spirometry was also conducted by trained study personnel in the participant‘s home 
using an ndd (new diagnostic design) Easy on-PC spirometer and followed the 
ATS/ERS guidelines (Miller et al, 2005). Each child had their spirometry taken before 
and after 4 puffs of Salbutamol inhaler via a large volume spacer, where they blew into 
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the machine 8 times to obtain the FVC and FEV1.  
5. Data Management and Analysis 
Data safety and monitoring 
There was no need for data safety and monitoring as no participants were being 
enrolled and no new data was collected. The original studies were low risk 
observational studies carried out under ethical approval.  
Data analysis 
This was a descriptive analysis of secondary data. Data have already been collected. 
All statistical data analysis was performed using Stata version 14.2 statistical software 
(Stata Statistical Software: R.14; StataCorp LLC, College Station, TX) and R software.  
The characteristics of the study population were explored using descriptive statistics 
and univariable analysis. Summary statistics were calculated for continuous variables 
and histograms were used to show distributions of numerical data. Frequency tables 
were used to summarize categorical variables. Scatter plots were used to explore 
associations between two continuous variables. Box plots explored the associations 
between continuous and categorical variables. Contingency tables and Chi squared test 
was used to identify associations between two categorical variables.  
The prevalence (95% confidence intervals) of poor quality traces (abnormal BEV and 
EOTV) was estimated and regression analysis used to identify variables associated with 
poor quality traces. The associations of suboptimal spirometry were described on 
selected variables (table 1).  
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To determine the relationship and its strength between spirometry parameters with 
outcomes (primary outcome, quality and secondary outcome, acceptance), binary 
logistic regression was performed with the statistical significance set at alpha = 0.05. 
For the primary outcome, quality, each grade (A, B, C, D and F) was analysed as an 
independently and categorized as Yes or No. Clinical factors affecting spirometry 
parameters were identified from literature. The BEV and EOTV of each individual 
accepted manoeuvre was described and the variability within manoeuvre identified. 
These parameters were also compared with the other two manoeuvres of an individual 
(between manoeuvre variability).  
Table 1 List of variables for data analysis 
 Variable Type 
Demographic Information Gender Binary 
Age  Continuous  
Height Continuous 
Weight  Continuous 
Ethnicity  Nominal  
Tests Test date Discreet 
Test stage Ordinal  
Spirometry Parameters  FEV1 Continuous 
FVC Continuous 
FEV6 Continuous 
FEV_FVC Continuous 
FET Continuous 
BEV Continuous  
EOTV Continuous  
Outcomes Quality Ordinal (A, B, C, D & F) 
Acceptance Binary (Yes/No) 
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Study measures 
Important variables that were analysed included the BEV, FET, EOTV (variables for 
acceptability) and FVC, FEV1, FVC/FEV1 (variables for repeatability). Variables of the 
relative and absolute differences of the FVC and FEV1 were the DFVC, DFVC%, 
DFEV1 and DFEV1% (See supplementary table 7 page 83 for definitions). Variables 
considered as  predictors of quality were clinical factors such as the age, gender, weight 
and height. 
6. Ethical considerations 
This was an analysis of secondary data and so comprised no direct risk to study 
participants. No participants were enrolled for this analysis, no new data was collected. 
The study contributing data was carried out under ethically approval and conducted in 
Malawi in children. The CLHS study titled, ―Child lung health and exposure to household 
air pollution in rural Malawi‖, by Rylance et al (2017) was approved by the College of 
Medicine Research Ethics Committee (COMREC) p.07/16/1994 in Malawi and Liverpool 
School of Tropical Medicine Research Ethics Committee (LSTM REC) 16-040 
(Appendix B and C).  
Ethical approval for this study was sought with the Faculty of Health Sciences Human 
Research Ethics Committee, University of Cape Town. 
Informed consent process 
All children participants in the CLHS study provided assent with parental or proxies‘ e.g. 
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main carer consent. All study materials, including consent forms, were provided in 
Chichewa, the local language. Trained study field workers administered informed 
consent during home visits. 
A written information sheet, using the University of Malawi, College of Medicine 
template was used before consent to participate was obtained and this was read out to 
all participants in English or Chichewa to accommodate those who could not read. 
Written informed consent was obtained from all participants and those who were unable 
to sign the consent form made a mark, witnessed by a person independent to the study. 
Description of risks and benefits 
This was an analysis of de-identified secondary data, and as such there were no direct 
risks to the individuals from whom data was used. The source data studies were low 
risk observational surveys that represented very low direct risk to study participants. 
Individuals were not identifiable as all personal identifiers were removed.  
There are no direct benefits to study participants, as data collection was already 
finished. However, the findings of this study may provide better insight and 
understanding of the importance of good quality spirometry measurements for improved 
diagnosis of lung function in children. Prompt and proper diagnosis of lung function is 
necessary for proper management of disease, which would improve the quality of life of 
the populations. This would also reduce the burden of lung disease hence reducing 
economic costs associated with these diseases. Understanding the variation of 
spirometry in children could be a base for further research on other possible diagnostic 
tools for those groups who fails to provide good quality spirometry.  
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Privacy and confidentiality 
Data in the proposed study was electronically kept in the researcher‘s laptop and 
supervisor‘s desktop which are protected by passwords. An encrypted, password 
protected external hard drive was used for back up. All data was provided without 
personal identifiers. This information is only accessible to the supervisor and 
researcher. 
Findings from this study may be shared through publication in peer reviewed journals 
and the UCT library.  
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1. Introduction 
1.1. Background and objectives of literature review 
The rise of chronic respiratory diseases (CRDs) presents a new challenge to the ever-
increasing burden of non-communicable diseases (NCDs) (Wang et al, 2015 and De-
Graft Aikins et al, 2010). According to statistics from the World Health Organization 
(WHO), NCDs account for at least 63% of global deaths of which 3.9 million deaths are 
reported to be linked to CRDs (Wang et al, 2015 and De-Graft Aikins et al., 2010). 
CRDs are the fourth leading cause of NCDs deaths worldwide (GBD, 2013), with 
interstitial lung disease and pulmonary sarcoidosis, displaying a substantial increase of 
51·5% in overall mortality rates between 2005 and 2015, to 121 800 deaths. The age-
standardized rates, also increased by 14·1% (Wang et al, 2015). Moreover, respiratory 
disease has been projected to presents the highest global statistics in the following 
decades (WHO, 2013 and De-Graft Aikins et al., 2010). In addition, respiratory diseases 
affect the global economy causing an estimated 4.7% of global disability-adjusted life 
years (DALYs), with two thirds resulting from chronic obstructive pulmonary disease 
(COPD) and one fifth due to asthma (Wang et al, 2015). 
In children globally, respiratory disorders account for considerable morbidity and 
mortality. They are the reason behind most children hospitalizations and hospital visits 
(Jat, 2013). In as much as morbidity and mortality caused by NCDs occurs mainly in 
adulthood, initial exposures to associated risk factors present early in life. Children often 
die because of treatable NCDs, and this will be the case if comprehensive care which 
involves health promotion and disease prevention and control not provided (WHO, 
2013). The most challenging aspect of this situation is that governments in many 
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countries have not given CRDs as much attention as they require. 
Information on CRDs is very limited despite the high burden of NCDs in low and middle-
income countries (LMICs) where CRDs are common in all age groups (Bousquet et al, 
2003). In sub- Saharan Africa (SSA), information regarding the estimates of prevalence, 
natural history, and associated mortality and morbidity of diseases is lacking due to 
scarcity of data (Beran et al, 2015; Bousquet et al., 2003 and Meghji et al, 2016). The 
limited available information strongly suggests that a high burden of CRDs (Finney, 
2013 and Buist, 2007) is to be expected in this region due to high exposures to risk 
factors of respiratory pathology (Stocks, 2013). Common risk exposures associated with 
abnormal lung function are: air pollution; tobacco smoking; and respiratory infections 
(Bousquet et al, 2003). 
A recent study that was conducted in a Malawian population found that more than 40% 
of the adult population had abnormal lung function (spirometry restrictions), attributed to 
high biomass exposures and high HIV prevalence (Meghji et al, 2016). Other ecological 
and prospective studies have also shown a relationship between restrictive lung disease 
and low respiratory volume, which is the main cause of mortality (Burney et al, 2011 and 
2014). 
However, without quantifiable research on the burden of lung diseases measured by 
lung function, CRDs cannot be understood, and planning of interventions may be 
misguided. Bousquet et al (2003), suggested the need for research (Starfield, 2001) to 
evaluate the burden and magnitude of the diseases, trace the history of disease 
correlates, discover and suggest outcomes and alternatives to account for associates, 
and investigate possible discussions and interventions. 
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Measuring lung function is one way to estimate the burden of disease among 
populations. To better understand lung function, it can be linked back to the general 
concept of lung development from the early years of life to adulthood.  
The objectives of this literature review are to: 1) provide an overview of the lung disease 
burden as measured by lung function in sub Saharan Africa; 2) review studies 
investigating spirometry in children; 3) describe variations in spirometry reads and 
factors associated with the quality of spirometry in children; and 4) review 
epidemiological studies investigating the quality and interpretation of spirometry in 
measuring lung function. 
1.2. Literature search strategy 
Literature was searched through Google Scholar and Pubmed electronic search tools 
for systematic reviews, peer-reviewed articles and guidelines published up until January 
2019. Epidemiological studies on lung function testing using spirometry were included in 
this review. Available studies conducted in Low and Middle-Income countries, 
international studies, including all study designs were used in the review. Also, relevant 
articles suggested by these search engines and relevant literature from reference lists 
of articles examined were considered. Search terms were used in combination and 
alone (see APPENDIX B). 
PubMED: (http://www.ncbi.nlm.nih.gov/pubmed/) and, Google Scholar: (https://google-
scholar.uct.ac.za/).    
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Figure 2  Literature search flow diagram 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 
For more information, visit www.prisma-statement.org. 
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2. Lung development and Function 
A better understanding of the respiratory physiology in children is important in the 
investigation of lung function (Jat, 2013). Lungs generally follow several distinct 
developmental stages, and these include: the embryonic stage; the pseudo glandular, 
canalicular, saccular, and alveolar stage; and the extended stage of equilibrated lung 
development (Maritz et al, 2005). The pulmonary alveoli and the airways that are 
connected to them, grows and matures later in the fetal life or even after birth (Maritz et 
al, 2005). These are the center for gas exchange in humans and are prone to placental 
insufficiency, premature birth and infections due to their developmental timing (Maritz et 
al, 2005). Compromises occurring during these critical phases of lung development can 
permanently alter the structure and function of the lungs, resulting in long-term adverse 
effect of the respiratory health of the foetus, infant and later in life (Maritz et al, 2005).  
In children, lung function develops alongside child‘s growth due to their dynamic and 
rapid growth phase. Lung volume and airway size increases rapidly in early childhood 
when growth is also rapid (Jat, 2013). Lung function peaks in early adulthood, and then 
begins to decline steadily with age (Becklake et al, 1993 and Hibbert et al, 1995). 
The development of lungs, like any other organ, is greatly affected by conditions of the 
pre-and postnatal environments (Maritz et al, 2005). Exposure to determinants of poor 
lung growth and function, according to findings of epidemiological research, may make 
lungs ineffective gas exchangers and could increase the risk of respiratory symptoms, 
illness and disease in adolescence and adulthood (Jackson, 2000). Important pre-natal 
conditions include limited nutrients and lack of oxygen and exposure to nicotine via 
maternal tobacco smoking (Maritz et al, 2005). Lung function can also be influenced by 
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prematurity, ethnicity, weight, age, sex and other environmental factors (Jat, 2013) 
causing variability within and between the population.  
3. Lung Function Testing 
Maximal expiratory ﬂow/volume (MEFV) measurements have become the cornerstone 
of pulmonary function testing (PFT) since its introduction in 1947 (Arets et al, 2001). In 
children, however, lung volumes and air flow measurements are not used as frequently. 
PFTs are now an invaluable and widely used tool in assessing, diagnosing and 
monitoring respiratory conditions in adults and children (Arets et al, 2001). In children, 
however, lung volumes and air flow measurements are not used as frequently as in 
adults, due to the common obstructive nature of lung function disorders in children 
compared to restrictive lung diseases. The choice of PFT in children largely depends on 
the developmental stage of the child. Age has a huge influence on the feasibility, 
assessment and interpretation of PFT, which varies among young and older children 
(van den WIJNGAART et al, 2015).  
Beydon et al (2007) proposed that an ideal PFT would be applicable to all ages, be 
easy to perform, not harmful, be repeatable, and highly sensitive to growth changes, 
and be able to distinguish between normal and abnormal lung function, and be well 
received by all parties involved. For lung function, nowadays, the most common 
diagnostic instrument used is spirometry (Giner et al, 2014). This is regarded as the 
gold standard for lung function measurements in many settings globally and in LMICs 
(van den WIJNGAART et al, 2015). 
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3.1. Spirometry in measuring lung function 
Spirometry is a useful, safe, non-invasive investigation tool for diagnosing, managing, 
and monitoring lung function and a number of respiratory conditions (Jat, 2013), through 
measuring lung dysfunction (Giner et al, 2014). It is used clinically to distinguish 
between normal and abnormal function of lungs. This instrument measures lung 
capacity whereby low lung volume, which is the inability to inhale fully, is considered 
sub-optimal lung function. This condition is called restrictive lung disease (Miller et al, 
2005). A lung condition can also be obstructive when the lungs fail to fully exhale air. 
The ability of the lungs to inspire to full capacity and forcefully expire at a given point in 
time is recorded by the spirometer and then translated and used as an indication of a 
healthy or ill lung. Measurements are based on the spirometry estimates which are 
clinically interpreted to aid in the diagnosis of lung function. They also provide a useful 
diagnostic tool for many other respiratory diseases in children such as cystic fibrosis, 
asthma, and congenital or acquired airway malformations (Jat, 2013). 
3.2. Indications of lung function spirometry in children 
Spirometry testing has been commonly used for monitoring respiratory conditions in 
adults but has been historically underused or incorrectly interpreted by paediatricians 
treating children with respiratory disease (Jat, 2013). In young children, the test has 
always been considered ineffective as this age group would not voluntarily produce 
breathing manoeuvres whereas adults would. However, currently the use of better 
equipment that is computerized with updated regional reference values, provision of 
incentives, and presence of modified acceptability and repeatability criteria, has made it 
feasible to carry out reliable spirometry in children (Aurora et al, 2004; Masekela et al, 
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2013; Nystad et al, 2002; and Veras et al, 2011).  
Spirometry has been successful as a diagnostic test in symptomatic children such as 
children with persistent wheezing (Constant et al, 2011); or for monitoring purposes, for 
example in children with asthma and cystic fibrosis (Holt et al., 2006 and Dundas et al, 
2006). It has been considered an important component in reviewing asthma control and 
cystic fibrosis disease progression. It is also frequently used in measuring lung function 
for many pulmonary diseases including haematological disorders and chest deformities. 
In some instances, it has been helpful in ascertaining preoperative lung function 
(Chong, 2011) or screening of schoolchildren for respiratory diseases (Constant et al, 
2011). There are reservations, however, regarding the correlation between clinical 
severity and spirometry measurements which could possibly be a source of 
misdiagnosis (Schneider et al, 2011 and Langhan, 2009). Therefore, spirometry is not 
considered a stand-alone clinical diagnosis. 
3.3. Spirometry test procedure 
The procedure for conducting a spirometry test in children aged >6 years is no different 
than in adults in terms of equipment and process (Jat, 2013). The success of spirometry 
tests can be measured by the quality of the information obtained from the test which 
does not only rely on the instrument but the competence from all parties involved (Giner 
et al, 2014). There are three essential elements that should be emphasized when 
conducting the test in children. The first element is the ability of the person performing 
the test to detect errors and to interpret the results of the test (Jat, 2013). Technicians 
and all health professionals that are involved with lung testing must be thoroughly 
trained on paediatric spirometry (Giner et al, 2014 and Masekela et al, 2013). 
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 Secondly, the instrument itself must be appropriately selected and prepared as this 
would affect the quality of measurements (Miller et al, 2005). The accuracy of the 
instrument mostly depends on the manufacturer and selected equipment should fulfil 
the American Thoracic Society/European Respiratory Society (ATS/ERS) 
recommendations for spirometry (Jat, 2013). There are a variety of spirometry devices 
that are available on the market. 
Lastly, the test procedure should be well understood by the child through clear, friendly 
explanation (Jat, 2013). Older children usually do not have a problem producing good 
measurements; however the younger age-groups require attention and support (Giner 
et al, 2014). Incentives are also often used in this age group to ensure optimum 
performance. It is the responsibility of the individual doing the procedure to ensure that 
proper procedures are being followed to ensure precise spirometry reads and 
manoeuvre measurements. Good quality measurements are necessary to be able to 
use a spirometer to correctly distinguish between normal and abnormally functioning 
lungs. 
3.4. Selection of the appropriate test manoeuvre 
The most important parameters of lung function measured by a spirometer are the 
forced volume capacity (FVC) and the Forced Expiratory Volume (FEV1). FVC 
measures the amount of air starting from full inspiration to a forceful expiration, which is 
as complete as possible, and the volume expired during the first second (s) of the FVC 
manoeuvre is the FEV1 (Miller et al, 2005). These are objective and less prone to bias 
(Jat, 2013), thus are reliable measures to correctly detect lung abnormality. 
Together these estimates are used to calculate a FVC/FEV1 ratio which gives insight 
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into the clinical lung function disorder present i.e. obstruction or restriction. FVC and 
FEV1 are usually represented in most studies as z-scores to account for height, age, 
and weight (Miller et al, 2005), which are factors known to directly affect lung volumes 
and influence the spirometry outcomes. Other parameters are measured but rarely 
interpreted or analysed in clinical studies using spirometry. Additional measures 
available include the back extrapolated volume (BEV) and end of test volume (EOTV) 
which are necessary for FCV and FEV1 manoeuvre acceptability. 
An acceptable manoeuvre is characterized by three distinct phases (Miller et al, 2005) 
and (Enright et al, 2011). First phase is the maximal inspiration/inhalation “takes a deep 
breath”. This is the phase where a subject inhales rapidly and completely from 
functional residual capacity to total lung capacity meaning from normal breathing to the 
maximum point of inhaling. This is followed by ―blast‖ expiration, without or with minimal 
hesitation. This means that the client must forcefully ―blast‖ out the inhaled air from the 
lungs, reaching a “sharp” (high) peak flow during the first tenth of a second and a high 
average flow during the first second of the manoeuvre (FEV1). The last phase is the 
continued complete exhalation to the EOT (maximal exhalation effort). In this phase the 
client continues exhaling until all the air from the lungs has been fully exhaled. 
Each of these phases, is characterized by the differing amount of effort required 
(Enright et al, 2011). However, these requirements are often not easily met in certain 
instances i.e. measuring FVC becomes a challenge in elderly people where the 
prevalence of airflow issues tends to be high. Therefore, a vital capacity (VC) is 
recommended for patients with signs of dizziness to avoid syncope. A VC allows for 
reduced effort or maximal forced expiration (Miller et al, 2005). 
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4. Spirometry Quality 
4.1. Acceptability and repeatability of spirometry 
The acceptability and repeatability of spirometry tests is a useful indicator of spirometry 
quality and this is necessary for results that are used for lung function diagnosis. In the 
United States, for instance, the current ATS/ERS standards base acceptability and 
repeatability of a test (Miller et al, 2005) on the technologists‘ ability to achieve the set 
goals in 90% of tested adult participants. This requires that technologists are well 
trained and spirometry test are hospital-based (Enright et al, 2004). 
 
Manoeuvre acceptability is defined by the BEV at the beginning of the test and the 
EOTV at the end of the test (Miller et al, 2005). These parameters should be 
satisfactory for a good trace measurement (table 1). During manoeuvres, technicians or 
clinical personnel, monitor the trace while continuously encouraging clients to give to 
their full capacity. Children have proven to have challenges meeting the quality criteria, 
set for adults, and modifications are mentioned in the ATS/ERS statement on PFT in 
preschool children (Beydon et al, 2007). A BEV of <80mL or 12.5% of the FVC is 
considered acceptable for children that are less than 10 years old (Jat, 2013).  Arets et 
al, 2001, proposed new acceptability and repeatability criteria for spirometry to 
accommodate children which include the BEV <0.12 L for children under 15 years old 
and <0.15 L for older children above the age of 15 years; and FET >1s and >2 s for 
children <8 and >8 years old. 
 
EOT criteria is especially difficult to meet by very young children when compared to 
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other acceptability criteria (Miller et al, 2005) necessitating the development of new EOT 
criteria specific for paediatrics (Desmond et al, 1997). Instead of the plateau at the end 
of test, for satisfactory expiration, a flow-volume curve that is rapidly rising to the peak 
flow and descends smoothly is accepted (Jat, 2013). This is in contrast to Miller et al 
(2005) statement that manoeuvres that don‘t meet the EOT criteria do not qualify for 
selection of the 3 acceptable manoeuvres. For subjects who terminate manoeuvres 
early, FEV1 may be used or reported depending on the length of exhalation. 
 
Manoeuvre reproducibility is defined by the FVC or FEV1. The ATS proposed the 
absolute difference in FVC or FEV1 (DFVC or DFEV1), as a criterion of reproducibility 
(American Thoracic Society, 1987) whilst the ERS mention the use of the relative 
difference criterion (Quanjer et al, 1993). A study conducted by Arets et al in children 
experienced in MEFV found that the DFVC or DFEV1 was easily met by the most 
children. The criterion in their findings however, was age-dependent and was not 
applicable to all ages. They, therefore, recommended the relative criteria (%DFVC or 
%DFEV1) as appropriate in paediatric practice since they were made to control for 
changes in the absolute magnitudes of measurements with pulmonary development 
(Arets et al, 2001).  
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Table 1 Acceptability and repeatability criteria for spirometry manoeuvres in children. 
Adapted from Miller et al., 2005 
Spirometry Acceptability Criteria 
1. Good start:  
 The inhalation is good 
 BEV of <5% of FVC or <100mL if FVC <1000mL, whichever is greater 
(For children of 6-12 years of age) 
2. Satisfactory exhalation: 
 Expiratory Time (ET) of 3 seconds 
 EOTV is when a plateau in the volume-time curve is reached or if child 
cannot or should not continue to exhale. 
Repeatability criteria 
A maximum of three acceptable traces are required: 
 The 2 largest values of FVC must be within 150mL of each other or within 
5% FVC or <100mL if FVC <1000mL 
 The 2 largest values of FEV1 must be within 5% FVC or <100mL if FVC 
<1000Ml 
Other criteria for good quality traces 
Manoeuvres should: 
Be without coughs through the first second (s) of exhalation 
 Have no early cut off or termination 
 Have maximal efforts throughout 
 Have no leaks 
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 Have no obstruction of mouthpiece 
 Have no glottis closure influencing measurement 
 
4.2. Quality Assessment and Variability 
A spirometer is designed with an inherent quality evaluation system which assigns 
grades to manoeuvres from A, B, C, D, E and F (table 2). Each grade is a measure of 
quality and is defined by a set of requirements that needs to be satisfied for a test to 
qualify to be in that category. Acceptability represents each measure‘s ability to meet 
stipulated thresholds for that measure, according to quality standards such as the 
ATS/ERS 2005. 
Table 2. Spirometry quality grading system. Reproduced from Culver et al (2017) 
Grade: Criteria: 
A ≥3 acceptable tests with repeatability within 0.150 L (for age 2–6, 0.100 L), or 
10% of highest value, whichever is greater 
B ≥2 acceptable tests with repeatability within 0.150 L (for age 2–6, 0.100 L), or 
10% of highest value, whichever is greater 
C ≥2 acceptable tests with repeatability within 0.200 L (for age 2–6, 0.150 L), or 
10% of highest value, whichever is greater 
D ≥2 acceptable tests with repeatability within 0.250 L (for age 2–6, 0.200 L), or 
10% of highest value, whichever is greater 
E 1 acceptable test 
F No acceptable tests 
 
4.2.1. Within-manoeuvre sources of measurement errors and variability 
Issues preventing the meeting of the ATS/ERS 2005 recommendations include the 
failure to achieve maximal effort and this has a direct influence on the quality of the 
trace, causing measurement errors. Poor efforts may occur during any (or all) of the 
manoeuvre phases (Enright et al, 2011). 
 34 | P a g e  
 
The most common problem is sub-optimal effort during inhalation which could be easily 
identified by comparing multiple manoeuvres wherein unique FEV1 and FVC are 
created that are not reproducible. This problem is often a result of poor interaction 
between the subject and the technologist (Enright et al, 2011). A submaximal inhalation 
falsely reduces PEF, FEV and FVC (all of the results, except for the ratios). 
Also, in each trace two common issues can be identified; a hesitant start and a slow 
start or poor exhalation effort (Enright et al, 2011). The former often result to a high BEV 
start which renders the manoeuvre unacceptable according to the ATS guidelines as it 
creates measurement errors in the FEV1 especially.  A slow start or poor exhalation 
effort causes long peak expiratory flow time (PEFT) another source of error (Enright et 
al, 2011). A submaximal blast during the second phase wrongly underestimates the 
PEF, affecting the FEV1, and increases the FVC measures. 
Premature terminations or manoeuvres that ―quit too soon‖ cause a false reduction of 
the true FVC and can be identified by a high EOTV (Enright et al, 2011). Premature 
finishes are usually flows ending at above 10% of peak flow (Jat, 2013). For example, 
adults are expected to achieve an FET >6s, including an ―obvious plateau‖ in the 
volume-time curve as per the ATS/ERS 2005 recommendations (Enright et al, 2011). 
Another study found that expiratory time (TE) was a source of another common error, 
the frequent manoeuvre lasting <6s. This was found mostly in younger subjects where 
5.1% of all performed manoeuvres, causing the most defects (Giner et al, 2014). 
4.2.2.   External sources of measurement errors and variability 
The potential for systematic errors and increased random errors in studies involving 
 35 | P a g e  
 
different spirometry technicians or teams is very high (Künzli et al, 1995). Measurement 
errors such as systematic measurement errors between technicians within a team or 
between teams are an important concern requiring attention (Künzli et al, 1995). If not 
taken into consideration systematic errors in lung function testing could bias the results 
by either underestimating or over-estimating spirometry outcomes. High random 
measurement variability leads to false negative conclusions by obscuring the effects of 
the exposure (Künzli et al, 1995). 
Separate quality control studies, involving 23 experienced technicians and eight teams, 
were conducted for the (Swiss study on air pollution and lung diseases in adults 
(SAPALDIA) to test for technician, team, device and within-subject variability-related 
measurement errors (Künzli et al, 1995). These studies were focused on both 
systematic and random measurement errors. They were aimed at finding out if there 
was any systematic measurement bias across technicians within each team or across 
eight teams (Künzli et al, 1995). These studies also sought to determine if there was 
evidence for systematic errors across the eight SAPALDIA pulmonary function devices 
(one device per team) and to describe ways in which within-subject variability measured 
with different technicians or devices compare to the expected biological within-subject 
variability, given only one technician and one device (American Thoracic Society, 1991). 
Findings from these studies found that there were no systematic errors due to 
technician, team or device (Künzli et al, 1995).   
Technician effect studies showed no team effect. However, these studies were limited 
by power, potential interactions between subjects and technicians in the fieldwork, and 
recruiting unhealthy subjects which could have increased total variability (Künzli et al, 
 36 | P a g e  
 
1995). On the other hand, Giner et al, (2014), suggests that individual technologists 
conducting the test are the main source of variability in spirometry test quality. Masekela 
et al., (2013) emphasizes on the importance of dedication and competence of lung 
function technologist for successful spirometry. However, Enright et al, 2011 argues that 
no matter how competent technicians could be in doing the procedure in terms of 
training and other efforts to improve test success, there will always be at least 10% 
failure rate. 
However, further investigation showed evidence of important internal error sources 
(device-related), which could not be easily detected even by trained technicians (Künzli 
et al, 1995). These unrecognizable technical problems could be hardware and software 
errors found in modern device and could introduce errors on any day, with any device. 
This makes the instrument, another good source of variability (Giner et al, 2014). 
Spirometry measurements may vary with models of spirometers. There is therefore a 
great need for quality control in spirometry to ensure valid and reliable results  
4.2.3. Subject-related sources of measurement errors and variability 
Individual clients‘ characteristics could be a good source of measurement errors and 
may influence the success or failure of the test (He et al, 2014). Most often they are 
associated with inability to reach stipulated quality standards (Giner et al, 2014). The 
burden of lung disease (BOLD) study found that factors that influence a spirometry test 
quality includes younger age, female  children, higher education, lack of dyspnoea, 
higher pre- bronchodilator FEV1, poor bronchodilator response, and study site. 
However, these predictors of quality accounted for only 10% of the overall variability in 
test quality (Giner et al, 2014). Chhabra (2015), He et al, (2014) and Arigliani et al, 
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2016, stated that in addition to anthropometric measures other factors that may also 
influence spirometry measurements includes; environmental, genetic, socio-economic, 
technical and the inherent biological determinants of lung function (Becklake, 1986 ). 
Some of these factors cannot be adequately quantified and accounted for (Chhabra, 
2015).  
Spirometry errors are directly associated with sex and are frequently seen in females 
(Giner et al, 2014 and Liu et al, 2009). Gender is one of the major sources of variation in 
lung function (Cotes, 1979). FVC and FEV1 have been found to be higher by 10% to 
15% in males when compared to females of the same age and heights. This is the case 
even with the PEF rate, which is also high in males than in females. However, the 
FEV1/FVC ratio and the expiratory flow rates are slightly higher in females. These 
support the development of separate equations for males and females (Chhabra, 2015). 
For age, older patients are more prone to perform good quality spirometry. Poor 
performance is usually due to deteriorated lung condition which is common in this 
population. Surprisingly though, younger patients are usually the most spirometry-naïve 
subjects and tends to have more errors (Giner et al, 2014). Chhabra, (2015) and 
Chhabra et al, (2016), stated that age is a well-known source of lung function variation. 
There is a linear relationship between child growth and lung development. The rapid 
physiological changes of a child from birth to adulthood, directly influences the change 
in FVC and FEV1, which follows the growth pattern. The FVC and FEV1 increases up 
until it reaches  a plateau at the age of 20 years and begin to decline steadily after 40 
years, as the elastic coil is lost and closing volume increases (Chhabra, 2015).  
Additionally, height has been found to explain the maximum variability. This is due to the 
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positive relationship that height has with spirometry variables (Chhabra, 2015 and 
Chhabra et al, 2016).  
On another note, studies that directly compared pulmonary function in children from 
different ethnic groups confirmed the presence of ethnic differences in lung function in 
children (Rossiter et al, 1974; Korotzer et al, 2000; Jacobs et al, 1992 and Arigliani et al, 
2016), suggesting that the causes of these differences could be genetic (Strippoli et al, 
2013 and Arigliani et al, 2016). Ethnic differences were seen mostly for FVC and FEV1 
and were not significant for FEV1/FVC ratio and flow rates (Chhabra, 2015). 
Patients‘ characteristics that contributed to good quality measurements with fewer errors 
included previous experience with spirometry (Enright et al, 2011). The learning effect in 
some studies enhanced performance and reduced errors in patients who had previously 
performed spirometry (Enright et al, 2011).  
Other than patients‘ characteristics, underlying conditions, such as patients showing 
respiratory symptoms, airway obstruction, or bronchodilator responsiveness, are more 
likely to fail quality goals, especially the EOTV (Enright et al, 2011). It is not easy to 
avoid unexplained variability and this leads inaccurate results and contributes to the 
loss of certainty of estimates (Chhabra, 2015). 
Künzli et al (1995) stated that the primary goal to prevent systematic effects and reduce 
random measurement errors is to enforce quality on all levels of data collection. Other 
most effective tools include using available lung function testing standards or guidelines 
(Gardner et al, 1986), ensuring training to individuals conducting the tests, quality 
control and regular supervision (Künzli et al, 1995). They proposed that manufacturers 
 39 | P a g e  
 
should ensure that software versions are adaptable to enhance the technicians' effort in 
obtaining accurate unbiased assessment. When conducting research studies, the 
reliability and accuracy of device hardware and software should not be assumed by 
researchers but tested to ensure proper functioning in the field. Also, there should be 
comparison tests in place even before the study commences (Künzli et al, 1995). 
 
5. Interpretation of Spirometry 
The availability of appropriate reference data determines the reliability of interpretations 
of spirometry results (Stanojevic, Wade and Stocks, 2010). Reference data is useful in 
distinguishing between normal and abnormal lung function as well as in assessing the 
severity and nature of functional impairment (Stanojevic, Wade and Stocks, 2010). 
5.1. Normal Lung Function 
Generally, the definition of normality of lung function is another controversy due to its 
subjectivity. Normal lung function is mostly assumed based on data from a ―healthy 
population‖ wherein spirometry values ranges were obtained (Stanojevic et al., 2010 
and Chhabra et al, 2016). This range of values is deemed to represent ―normal‖ on the 
bases that it represents most individuals‘ values. A normal range is one in which 95% of 
the range of values from the ―healthy population‖ falls. Those with values outside of this 
normal range are said to have abnormal lung function and are often referred for further 
investigation. Since these values are derived from adult data, it becomes a challenge 
with children. Another question lies within the definition of a ―healthy population‖, 
especially as these lung function ranges are a reference on which all spirometry 
measurements and outputs are based. 
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Interpreting spirometry is a huge challenge embedded in the selection of appropriate 
reference values or misinterpretations where inappropriate equations were used. The 
increasing number of new and old published reference equations makes it more difficult 
to choose the appropriate ones (Stanojevic, Wade and Stocks, 2010 AND Chhabra et 
al, 2016). Inappropriate reference equations are a source of errors such as 
misdiagnosis and over or under diagnosis of disease, and their financial and human 
costs are very high. 
5.2. Reference values 
The use of different reference equations when measuring lung function is also another 
important source of variability in the interpretation of spirometry reads (He et al, 2014). 
This was more common before the Global Lung Function Initiative (GLI, 2012) 
developed multi-ethnic, all-age reference equations for spirometry which are now the 
new gold standard and have been adopted by many respiratory societies (Stanojevic et 
al, 2014). These become very useful in interpreting and presenting spirometry 
outcomes, especially the FEV1 and FVC incorporating multi-ethnic groups and all age 
groups.   
The GLI-2012 reference equations were developed to try and bridge the gap and 
address the implications of variable equations between populations and age groups 
which have been common for a long time. These were investigated in pre-school 
children in three countries in Sub-Saharan Africa (Angola, D. R. Congo and 
Madagascar), and were found to be appropriate (Arigliani et al, 2016).  
Reference equations provide a range of normal values which are compatible with 
normal lung function incorporating gender, age, ethnicity and body size of individuals 
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being investigated (Stanojevic, 2008). The use of different reference equations has led 
to elusive and extreme differences in findings reported by studies, based on the 
reference equations used (Quanjer, 2008). This highlights the importance of 
implementing updated and appropriate reference values for understanding the apparent 
lung function status of populations. 
Most commonly, different reference standards were used for children and adults 
including gender and age specific equations. However, these have been shown to have 
limitations with varying clinical impact. Some equations overestimate lung function 
(FEV1 and predicted FVC) e.g. the Knudson equations, by producing low predicted 
values (Stanojevic et al, 2014). These limitations were mostly observed in children as 
realised in the Wang–Hankinson equations derived from the National Health and 
Nutrition Examination Survey (NHANES) III data. There is also evidence of the under 
diagnosis or under reporting of asthma in children in LMICs in the literature (Olaniyan et 
al, 2019 and Mohammad et al, 2017). Another loophole with reference values, 
especially age specific ranges, was that the transition from early childhood to 
adolescence to adulthood showed outstanding differences that have the potential to 
lead to substantial misinterpretation. This would mean that a patient with disease would 
be more likely to have results that are in the normal range due to incorrect data (false 
negative/false re-assurance).  
The GLI-2012, therefore addressed these challenges by starting at 3 years of age. Such 
equations were aimed to improve interpretation of spirometry in paediatric practice as 
well as to enable appropriate assessment and disease management (Stanojevic et al, 
2014). Universal reference equations are also crucial in improving comparability within 
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and between research studies. This would also address the implications caused by 
using spirometry cut-offs that exist between studies which forms the basis for participant 
selection (i.e. 90% predicted FEV1). 
5.3. Steps for interpreting spirometry 
Interpretation of children‘s lung functions‘ using adult criteria is a challenge and another 
major cause of errors in interpretation for this population. Abnormal lung function in 
children, for instance, is defined by applying the fixed adult predicted FEV1 cut-offs of 
80% or 0.7 FEV1/FVC, which may cause misdiagnosis. Generally, the over reliance on 
fixed thresholds to define normal or abnormal lung function, magnifies misinterpretation 
problems regardless of well recognized age-related variations ((Stanojevic, Wade and 
Stocks, 2010). 
Jat, (2013) summarized the interpretation of spirometry results in four steps: the 1st step 
is the assessment of acceptability and repeatability of spirometry followed by the 
identification of test patterns (Normal, Obstructive, Restrictive, or Mixed), the grading of 
patterns for severity and lastly the diagnoses, treatment or further investigation of 
identified conditions. 
 
5.3.1. Assessment of acceptability and repeatability of tests 
Spirograms are used to assess test acceptability and repeatability. These are the flow-
volume curves which evaluate the BEV and volume-time curves which assess the EOT. 
The shape of the flow-volume curve is also useful in detecting errors and artefacts in the 
spirometry procedure which must be done first to ensure acceptability. They should 
comply with ATS/ERS standards (table 1). 
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5.3.2. Spirometry pattern and identification 
The results of a spirometry test may suggest the following ventilation patterns: normal; 
obstructive; restrictive; or mixed pattern (Quanjer et al, 1993 and Barreiro, 2004) (table 
3). Identification of abnormalities is through the analysis of the shapes of the flow-
volume curves and volume-time curves and comparing the values of test parameters to 
their z-scores which account for sex, age, height, weight, and ethnicity. 
A flow-volume curve that is sharply rising to a peak and descending at a 45° angle 
represents normal lung function (Aurora et al, 2004).. Mild to moderate airway 
obstruction is indicated by a concave curve whilst severe obstruction has an extended 
end like a rat‘s tail. A normal volume-time curve is also characterized by a sharp rise 
followed shortly by a plateau. Moderate to severe airway obstruction is indicated by a 
slow gradual rise with no definite plateau reached (Aurora et al, 2004). A restrictive 
pattern is shown by a small flow-volume curve whilst extra thoracic obstruction is shown 
by a flat FVC flow-volume curve without a peak. In younger children the convex shape 
of the flow-volume curve, which becomes more linear as the child grows, is due to the 
rapid emptying of the larger airways than the result in smaller lung volumes (Aurora et 
al, 2004). 
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Table 3 Spirometry pattern and identification. Adapted from Jat, 2013 
Four types of 
ventilation 
patterns 
Characteristics and Indications 
Normal spirometry - FVC:  >80% of predicted or above the lower limit of normal 
- FEV1:  >80% of predicted or above the lower limit of normal 
-  FEV1/FVC is suggestive of normal function. 
The obstructive 
pattern 
- Decreased FEV1 <80% of predicted or below the lower limit 
of normal 
- Decreased FEV1/FVC 
- Normal FVC (in severe obstruction). 
- Mid expiratory flow (FEF25-75%) below 60% of predicted 
(small airway patency/ airway obstruction) (Lebecque et a, 1993; 
Valletta et al, 1997 and Simon et al, 2010) 
The restrictive 
pattern 
- Predominantly decreased FVC 
- Normal or decreased FEV1 
- Normal or increased FEV1/FVC 
The mixed pattern - A decreased value of all three parameters (i.e. FEV1, FVC, 
and FEV1/FVC). 
- Normal expiratory flow but decreased inspiratory flow is 
suggestive of collapsible extra-thoracic airway obstruction (e.g. 
laryngeal paralysis) 
- Decreased maximal expiratory flow with normal inspiratory 
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flow suggests collapsible major intrathoracic airway obstruction. 
- If both inspiratory and expiratory flows are decreased, a 
fixed intrathoracic or extra-thoracic airway obstruction is likely 
(Pellegrino et al, 2005) 
 
5.3.3. Grading the severity of pattern identified 
Spirometry results have been found to correlate with asthma severity, requiring oral 
steroids, emergency department visits, and hospitalizations (Fuhlbrigge et al, 2006) in 
preschool children (Vilozn et al, 2005). The FEV1 (% predicted) together with other 
clinical features of an individual, classifies the severity asthma into mild, moderate, and 
severe persistent asthma (Stout et al, 2006) (table 4). 
Table 4 Grading severity of spirometry patterns in cases of asthma. Reproduced from 
Stout et al (2006) 
Severity FEV1 (% predicted) 
Mild obstruction FEV1 <100% to 80% 
moderate obstruction FEV1 <80% to 50% 
severe airway obstruction FEV1 <50% to 30% 
very severe obstruction FEV1 <30% 
 
5.3.4. Diagnosis, linkage to care or further assessment 
Spirometry alone does not provide aetiology or diagnosis of disease and should not be 
viewed in isolation of clinical evaluations, which should preferably be performed prior to 
spirometry. Instead, spirometry provides a pattern of ventilation and physiological 
pulmonary abnormalities, which aid diagnosis (Jat, 2013). These can be normal, 
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obstructive, restrictive, or mixed. In children, a typical example of the obstructive 
condition is asthma. Interstitial lung disease, pneumonia and pleural effusion show a 
restrictive pattern. Conditions such as cystic fibrosis may have either an obstructive, 
restrictive, or mixed spirometry pattern (Jat, 2013). 
 
Results from both the clinical assessments and spirometry measurements are therefore 
used to provide a basis for diagnosis of disease.  Patients diagnosed with these 
conditions may then be linked to care as necessary, i.e. referred for treatment, or 
subjected to further investigations of disease in advanced respiratory laboratories (Jat, 
2013). 
 
6. Conclusion 
Spirometry is a useful tool for lung function investigation, yet quality remains a major 
concern in children.  Despite, the modification of quality standards, the availability of 
better spirometers which have age-specific reference standards, intensive trainings and 
experience on paediatrics spirometry, the use of incentives to aid performance, young 
children still fails to meet good quality spirometry standards. Mostly they produce 
acceptable manoeuvres and maximal expiratory ﬂow/volume curves that are useful for 
interpretation; the reliability of measurements cannot be guaranteed in children. In most 
cases these measurements are based on low quality standards. Other alternatives, with 
less quality implications could be explored for young children. 
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Manuscript Abstract  
BACKGROUND AND OBJECTIVE: Despite spirometry being the most commonly used 
diagnostic test for lung function, the quality of measurements have not been evaluated in sub-
Saharan Africa. The objective of this study was to describe the quality and variation of 
spirometry reads in children, in a Malawian population. 
   
METHODS: This descriptive study involved secondary analysis of data contributed by the 
Children Lung Health study (CLHS), a cross-sectional survey, conducted in Malawi. Spirometry 
measurements from 802 children, aged 6-8 years were studied. The Acceptability criteria; start-
of-test (backward extrapolated volume (BEV)), end-of-test (forced expiratory time (FET) and 
EOTV (end-of-test volume) and Reproducibility criteria (absolute and relative difference 
(percentage difference between best and second-best FVC and forced expiratory volume in one 
second (FEV1) (DFVC, DFVC %, DFEV1 and DFEV1 %)) were applied to these manoeuvres. 
Statistical analysis was mainly descriptive statistics and logistic regression. 
    
RESULTS: The BEV was <0.15 L in 99% of the children and varied with height and weight. 
FET was >6 s in 3% and 5% of the younger and older age group respectively. The EOTV was 
<0.05 L in 85% of the children. Both FET and EOTV were significantly associated with 
younger, but taller children. The DFVC <200 mL criterion was met by 95% of the children; 
DFVC% <5% by 66%; DFEV1 <200 mL by 97%; DFEV1% <5% by 64% of the children. 
    
CONCLUSION: The failure for young children to meet all acceptable quality standards for 
spirometry proves a limitation of the measurement device and supports a re-evaluation of 
standards or technical amendments. 
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1. Introduction  
Lung function investigations have become the centre of knowledge used to understand the 
growing burden of non-communicable pulmonary diseases globally (Murray et al, 2012). 
Chronic respiratory diseases, such as chronic obstructive pulmonary disease, asthma, pneumonia, 
and other lung diseases, are an emerging public health concern in low and middle-income 
countries (Ahmed, Robinson and Mortimer, 2017). Proper and timely diagnosis of these 
conditions is critical for health care systems in countries highly affected by chronic lung 
diseases, especially in Africa (Buist et al, 2017). In children, asthma, which compromises lung 
function in adolescence and subsequently adulthood (Phelan et al, 2002), is a major chronic 
respiratory disease (Asher and Pearce, 2014) with high burden in Africa. Diagnosis of lung 
diseases should not rely only on clinical symptom assessments but should be confirmed by 
airflow limitation (Reddel et al, 2015), which is commonly measured by spirometry. 
 
Spirometry is a non-invasive method of lung function measurement, which is often used to 
distinguish between normal and abnormal lung function (Miller et al, 2005 and Levy et al, 2009). 
Spirometry measures lung capacity and is typically interpreted as normal, restrictive or 
obstructive. A recent study conducted in Malawi found a high prevalence of restrictive 
spirometry in adults, which is of great concern due to the relationship of restrictive spirometry 
with increased mortality (Meghji et al, 2016). However, there is very little research on measuring 
lung function in children in the sub Saharan Africa. Therefore, little is known about the burden 
of chronic lung diseases in children. 
 
The most important parameters of lung function measured by a spirometer are the Forced Vital 
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Capacity (FVC) and Forced Expiratory Volume (FEV1) (Barreiro and Perillo, 2004). FVC 
measures the volume of air starting from a point of full inspiration to a forceful expiration which 
is as completely as possible and the first second of the FVC manoeuvre is the FEV1 (Miller et al, 
2005). Together these estimates are used to calculate a FVC/FEV1 ratio which gives insight into 
the clinical disorder present i.e. obstruction or restriction. FVC and FEV1 are represented in 
most studies as z-scores to account for height, age, weight which are known to directly affect 
lung volume, and hence spirometry measures. Other parameters are measured but are rarely 
interpreted or analysed in clinical studies using spirometry.  Additional measures available 
include the back extrapolated volume (BEV) and end of test volume (EOTV) which are used to 
classify an FCV and FEV1 manoeuvre as acceptable. Spirometry relies on the quality of these 
measurements to provide meaningful result.  
 
The Department of Health (2004), and Commission for Healthcare Audit and Inspection (2009), 
and the Respiratory Alliance (2003), stated that high quality, reliable, diagnostic spirometry are 
critical elements underpinning improvements in quality of care and recognition of lung function 
conditions. The quality of spirometry measurements plays a major role in detecting lung function 
abnormalities, providing appropriate interventions, and planning health services. Therefore, 
accurate and reliable measurements are crucial in pulmonary function interpretation and 
documentation (Tan et al, 2014). In recent years, maximal expiratory flow/volume measurements 
have become the cornerstone of lung function testing, making spirometry the most common 
diagnostic and follow-up tool for children with respiratory conditions (Arets et al, 2001).  
 
The American Thoracic Society (ATS) and European Respiratory Society (ERS) describe the 
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quality of spirometry through criteria for acceptability and repeatability (Miller et al, 2005 and 
Pallegrino et al, 2005). Emphasis is placed on the start of the test (BEV), the EOTV, and the 
forced expiratory time (FET) as important determinants of test quality (Miller et al, 2005). 
These, if not taken into consideration, could be major sources of error and mismeasurement. 
Children have always been recognized as having the greatest challenge in meeting spirometry 
quality standards, which were originally designed for adults (Arets et al, 2001). However, this is 
changing due to improved technology of the test instrument which takes age into account, 
modified quality criteria, and improved trainings of health practitioners involved in spirometry.  
One study that evaluated the applicability of the ATS/ERS criteria for spirometry in school-age 
children (aged 5–19 years) found the end of test to be the most challenging criteria for most 
children, whilst younger children struggle to produce maximum effort at the start of the test 
(Arets et al, 2001). Other studies argue that meeting the criteria is age-dependent and older 
children have no problem meeting them. Some studies emphasize on technicians’ ability in 
obtaining maximal effort in children (Jat, 2013). 
 
This study describes the use of spirometry as a reference standard for testing lung function and 
clinical diagnosis in children aged 6 -8 years old in the sub-Saharan African population. The 
aims of the analysis were to evaluate the quality and variation of spirometry reads in children. 
Also, variables associated with quality (and variation) of spirometry (reads) were identified. 
 
2. Patients and Methods  
2.1. Study design and population 
This study was a secondary analysis of data collected as part of the Child Lung Health Study 
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(CLHS). The CLHS was a cross sectional survey assessing the prevalence and determinants of 
non-communicable lung disease in children aged 6-8 years, by measuring lung function and 
household-level particulate exposure (Rylance et al, 2017). The age range chosen reflected the 
younger age group (6 -7 years) included in the worldwide international study for asthma and 
allergies in children (ISAAC) trial (Rylance et al, 2017). Data used for the present study were 
collected from December 2016 to September 2017 in village-level clusters in Chikwawa that 
participated in the Cooking and Pneumonia Study (CAPS), Malawi (Havens, 2017).  
2.2. Ethics and consent 
 All participants assented to be part of the study and adults who participated in the Adult Lung 
Health Study (ALHS) and carbon monoxide exposure components of CAPS gave written 
informed consent for children aged 6 -8 years who were recruited from their households during 
home visits (Rylance et al, 2017). Anthropometric measurements were taken from eligible 
individuals and spirometry was conducted pre- and post-bronchodilator treatment by trained and 
certiﬁed staﬀ. The CLHS study entitled, “Child lung health and exposure to household air 
pollution in rural Malawi”, by Rylance et al, 2017 was approved by the College of Medicine 
Research Ethics Committee (COMREC) p.07/16/1994 in Malawi and LSTM Research Ethics 
Committee (REC) 16-040. Ethical approval for this study was given by the Faculty of Health 
Sciences Human Research Ethics Committee, University of Cape Town (HREC REF 669/2018). 
 
2.3. Data collection 
Spirometry was performed according to the ATS/ERS guidelines (Miller et al, 2005) using an 
Easy on-PC spirometer (new diagnostic design, ndd) in the participant’s home. Study staff 
received training in paediatric spirometry from experienced researchers and Spirometry Training 
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Services Africa (Rylance et al, 2017). Spirometry was performed before and after four puffs 
(total 400 micrograms) of a Salbutamol inhaler via a large volume spacer (Rylance et al, 2017). 
The child would blow into the machine a maximum of eight times, to record the maximum lung 
volume (FVC) and FEV1.  
 
Lung function quality assurance was achieved through full training of study staff on performing 
paediatric spirometry tests before the study commenced (Rylance et al, 2017). Standard 
operating procedures (SOP) were developed to aid study staff in achieving a quality output and 
reduce variability of results. Study equipment was calibrated and maintained according to the 
manufacturer’s instructions. Spirometry traces were reviewed by two clinicians independently 
for adherence to within-manoeuvre and between-manoeuvre quality criteria. Study field workers 
were supervised by senior team members to ensure standard operation procedures (SOPs) were 
adhered to and to identify any additional training needs (Rylance et al, 2017). Test sessions were 
evaluated automatically by the Easy on-PC spirometer, which graded quality into five categories 
(A, B, C, D and F) and a minimum of three acceptable manoeuvres were obtained for each child. 
2.4. Statistical analysis 
Descriptive statistics were calculated for both the pre- and post-bronchodilator time points to: 
describe the characteristics of the study population; and summarize the spirometry indices for 
individual manoeuvres. Frequency tables were used to summarize the primary outcome, quality 
and secondary outcome, acceptance. Histograms were used to show distributions of numerical 
data (discreet or continuous). Scatter plots were used to display bi-variate data and show the 
strength of the relationship between spirometry indices and anthropometric variables. Box plots 
were used to graphically show selected descriptive measures for indices and quality outcomes. 
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Contingency tables and Chi squared test were used to identify associations between quality and 
acceptance outcomes. Study measures included the BEV, FET, EOTV (variables for 
acceptability) and FVC, FEV1, FVC/FEV1 (variables for repeatability). For the relative and 
absolute differences (DFVC and DFEV1) were used. (See supplementary table 7 pg 83 for 
definitions). Predictors of quality were Age, gender, weight and height. 
 
Univariable analysis (binary logistic regression) was performed to: determine the relationship 
and its strength between spirometry indices with primary outcome, quality and secondary 
outcome, acceptance; to determine the associations between spirometry parameters and clinical 
factors considered as predictors of quality; and to identify variables associated with poor quality 
traces. Each quality grade (A, B, C, D and F) was analysed independently and categorized as Yes 
or No. Proportions using contingency tables and Chi squared test were used to estimate the 
prevalence (95% confidence intervals) of poor quality traces (suboptimal BEV, FET and EOTV). 
All tests were two-tailed in nature and were performed using Stata version 14.2 statistical 
software (Stata Statistical Software: R.14; StataCorp LLC, College Station, TX) and R software. 
A p value < 0.05 was considered statistical signiﬁcant. 
3. Results 
3.1. Participation and demographics 
The analysis of the pre- and post-bronchodilator spirometry data included data from all 802 
participants from village-level clusters of Chikwawa in Malawi. Participants were African 
children (99.9%); 48% were males; 47% below 7-years-old (young children) and 53% above 7-
years-old (older children); mean age was 7.1 (+0.8) years; mean height was 1.2m (+ 0.1) and the 
mean weight was 19.9 (+2.8) kg/m2 (Table 1). A total of 12% of the children did not perform 
 68 | P a g e  
 
post-bronchodilator spirometry. These were mostly young children with a mean age of 7.0 (+0.8) 
years); who were short, with a mean height of 1.2m (+ 0.1) and were females (51.0%). 
 
Table 1 Baseline characteristics of the 802 children cohort at Pre and Post-bronchodilator time 
points. Values given as frequency (per cent) unless otherwise specified 
 
3.2. Quality assessment and Variability by the Easy on-PC spirometer 
The Easy on-PC spirometer automatically evaluated test sessions according to quality grades (A, 
B, C, D, and F) (Enright et al, 2011). Out of the 1508 test sessions conducted showed that 65% 
for pre-bronchodilator test sessions and 71% of post-bronchodilator tests sessions had adequate 
quality (Grades A, B and C); 12% in both time points had D quality; 23 % and 17% had F 
quality in pre-bronchodilator and post- bronchodilator sessions respectively. Quality grades A 
and F were associated with older age, male gender and taller height (Table 2(a)). 
 Total Pre-BD Post-BD Subject without 
Post-BD 
Study subjects (n) 802 (100%) 802(100%) 706 (100%) 96(100%) 
Gender:        
Males 387 (48.3%) 387 (48.3%) 340(48.2%) 47(49.0%) 
Females 415 (51.8%) 415 (51.8%) 366 (51.8%) 49(51.0%) 
Ethnicity :     
African 801(99.9%) 801 (99.9%) 706 (100%) 96(100%) 
Asian 1 (0.1%) 1(0.1%) 0 (0.0%) N/A 
Age categories:     
<7 ( Young) 374 (46.6%) 374 (46.6%) 319 (45.2%) 41(42.7%) 
 >7 ( Older) 428 (53.4%) 428 (53.4%) 387 (54.8%) 55(57.3%) 
Anthropometry (mean, 
SD) 
    
Age, yrs. 7.1 + (0.8) 7.14 + (0.8) 7.16 + (0.8) 7.0+ (0.8) 
Height, cm 1.2 + (0.1) 1.16 + (0.1) 1.2 + (0.1) 1.1 + (0.1) 
Weight, Kg 19.9 + (2.8) 19.8 + (2.8) 19.9 + (2.8) 19.2+ (2.7) 
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Table 2 (a) Risk factors associated with spirometry quality grades (A, B, C, D and F) in both the 
pre-and post-bronchodilator test sessions 
 Pre-BD Post-BD 
Risk factor Crude   Crude  
Grade A OR 95% C. I OR 95% C. I 
Age  1.65 1.37-1.99 1.22  1.01-1.49 
Gender: Male 0.64  0.49-0.85 0.76  0.57-1.03 
Height 89.46  8.96-893.01 6.97  0.60-80.88 
Weight 1.05 1.00-1.10 1.03  0.98-1.09 
Grade B     
Age 0.76  0.54-1.07 0.76  0.53-1.11 
Gender: Male 1.27  0.77-2.10 1.32  0.76-2.29 
Height 0.02  0.00-1.46 0.03  0.00-2.69 
Weight 0.93  0.85-1.02 0.93  0.84-1.03 
Grade C     
Age 1.02  0.72-1.45 1.34  0.94-1.92 
Gender: Male 0.89  0.52-1.53 1.18  0.67-2.07 
Height 0.39  0.00-30.94 25.38  0.26-2507.93 
Weight 1.01  0.92-1.12 1.06  0.96-1.16 
Grade D     
Age 0.77  0.58-1.02 0.83  0.62-1.13 
Gender: Male 1.30  0.85-1.99 0.83  0.52-1.31 
Height 0.66  0.02-20.48 0.05  0.00-2.29 
Weight 1.02  0.94-1.09 0.94  0.86-1.02 
Grade F     
Age 0.63  0.50-0.79 0.78  0.60-1.02 
Gender: Male 1.50  1.07-2.09 1.49  1.00-2.22 
Height 0.02  0.00-0.24 0.37  0.01-9.68 
Weight 0.95  0.89-1.01 1.00  0.93-1.07 
Narrative: statistically significant figures are written in bold. 
 
The Easy on-PC spirometer further evaluated test sessions by acceptance outcomes (whether 
manoeuvre was accepted or not). This study found that 77% of children had acceptable 1
st
 
manoeuvres, yet only 71% and 56% had acceptable second and third manoeuvres respectively. 
23% of children had an unacceptable 1
st
 manoeuvre and these also failed the second and the 3
rd
 
subsequent manoeuvres. However, 7% of children with an accepted first manoeuvre failed both 
the 2
nd
 and the 3
rd
 subsequent manoeuvres. Figure 1 shows the distribution of children through 
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the different manoeuvres by the acceptance outcomes. Acceptance of manoeuvres was associated 
with age, gender, height and weight (Table 3 (b)). 
 
 
 
Figure 1 Flow chart showing the distribution of children in the different manoeuvres by 
acceptance outcomes. Boxes represent acceptance outcomes and rows represent manoeuvres. 
Highlighted boxes mean there were no children with that outcome 
 
 
 
Ov ll Coho t 
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Table 2 (b) Risk factors associated with manoeuvre acceptance in both the pre and post 
bronchodilator test sessions 
 Pre-BD  Post-BD  
Risk factor Crude  Crude   
Manoeuvre 1 OR 95% C. I OR  95% C. I 
Age  1.58  1.26-1.99 1.27  1.00-1.66 
Gender: Male 0.67  0.48-0.93 0.67  0.45-1.00 
Height 65.33  4.14-1029.76 2.70  0.10-70.59 
Weight 1.05  0.99-1.12 1.00  0.93-1.07 
Manoeuvre 2     
Age 1.76  1.42-2.19 1.39  1.09-1.78 
Gender: Male 0.65  0.48-0.89 0.75  0.53-1.08 
Height 92.13  7.00-1212.71 10.17  0.52-197.99 
Weight 1.40  0.62-3.17 1.04  0.97-1.11 
Manoeuvre 3     
Age 1.83  1.50-2.23 1.39  1.12-1.72 
Gender: Male 0.64  0.48-0.85 0.71  0.51-0.97 
Height 99.13  9.02-1089.39 15.35  1.08-218.60 
Weight 1.05  1.00-1.11 1.05  1.00-1.12 
Definition of abbreviation; BD stands for bronchodilator 
 74 
3.3. Quality assessment and Variability by the ATS acceptability and repeatability 
criteria 
The ATS criteria for acceptability in children are BEV <100 ml, FET > 3 seconds and EOTV 
<50 ml; and for repeatability, variation in FEV1 (<200ml), FVC (< 200 ml) (Pellegrino et al, 
1994). Tables 3 (a) and 4 shows the mean, and SD for pre- and post-bronchodilator spirometry 
variables for all children according to the ATS/ERS criteria of acceptability and repeatability. 
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Table 3 Spirometry quality indices for the ATS/ERS criteria of acceptability (BEV, FET, 
EOTV), for each manoeuvre in the pre and post–bronchodilator spirometry tests 
 Pre-BD Post-BD 
 Mean SD (+) Mean SD (+) 
Manoeuvre 1     
BEV, L 0.05 0.05 0.05 0.02 
FET, sec 3.57 1.65 3.78 1.40 
EOTV, L 0.04 0.10 0.02 0.08 
Manoeuvre 2     
BEV, L 0.04 0.04 0.05 0.02 
FET, sec 3.59 1.75 3.69 1.41 
EOTV, L 0.05 0.11 0.02 0.08 
Manoeuvre 3     
BEV, L 0.04 0.04 0.05 0.04 
FET, sec 3.42 1.76 3.63 1.34 
EOTV, L 0.05 0.11 0.03 0.09 
 
Table 4 Spirometry indices for the ATS/ERS criteria of repeatability by manoeuvre of the pre-
and post–bronchodilator test sessions in the Child Lung Health Study. Data is presented as 
means and percentages 
  Pre-BD Post-BD  
 Mean Pred Pred% LLN Mean Pred Pred% LLN 
Manoeuvre 1         
FVC 1.12 1.39 80.57 1.11 1.14 1.40 81.43 1.12 
 FEV1 0.99 1.26 78.57 1.00 1.01 1.26 80.16 1.01 
FEV1/FVC 0.89 0.91 97.80 0.79 0.89 0.91 97.80 0.79 
FEF2575 1.36 1.67 81.4 1.05 1.49 1.68 88.69 1.05 
Manoeuvre 2         
FVC 1.08 1.39 77.70 1.11 1.09 1.40 77.86 1.12 
FEV1 0.95 1.26 75.40 1.00 0.97 1.26 76.98 1.01 
FEV1/FVC 0.88 0.91 96.70 0.79 0.89 0.91 97.80 0.79 
FEF2575 1.30 1.67 77.84 1.05 1.43 1.68 85.12 1.05 
Manoeuvre 3          
FVC 1.07 1.39 76.98 1.11 1.07 1.40 76.43 1.12 
FEV1 0.92 1.26 73.02 1.00 0.95 1.26 75.40 1.01 
FEV1/FVC 0.88 0.91 96.70 0.79 0.89 0.91 97.80 0.79 
FEF2575 1.26 1.67 75.45 1.05 1.40 1.68 83.33 1.05 
Definition of abbreviation: LLN stands for Lower Limit Normal. 
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Quality results for the ATS criteria of acceptability (BEV, FET and EOTV), and repeatability 
(FEV1 and FVC) using the absolute and relative differences for the pre and post–bronchodilator 
spirometry test sessions are presented in Tables 5. Quality assessments were conducted for 
different thresholds of the ATS criteria. This study found that more than 95% of all the children 
met the criteria for acceptability and above 85% children met the repeatability criteria when it is 
relaxed. Acceptability variables were taken from the “best manoeuvre” and repeatability 
variables were the differences between the highest and second highest manoeuvres. 
 
The acceptability of manoeuvres for the children was mostly dependent on FET other than BEV 
and EOTV when the "best manoeuvre” was analysed. Only FET was associated with 
acceptability of manoeuvres for the children, OR 1.63 (95% CI: 1.44, 1.83). The BEV showed no 
association and the EOTV was too small for analysis. 
  
 Figure 3 Odds ratios (OR) and 95% Confidence Interval (C.I.) of "best manoeuvre” indices and 
acceptability 
FEV1 
FEV1/FVC 
FEF2575 
EOTV 
FET 
Parameters 
FEV6 
BEV 
FVC 
VCmax 
8.90 (3.85, 20.93) 
2.78 (0.41, 18.71) 
2.34 (1.61, 3.40) 
(Excluded) 
1.63 (1.44, 1.83) 
Crude OR (95% CI) 
4.37 (2.17, 8.79) 
0.00 (0.00, 0.10) 
3.21 (1.63, 6.33) 
3.21 (1.63, 6.33) 
    1 0 5 10 15 20 
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Table 5 Proportion of children with manoeuvres that met the American Thoracic Society and 
European Respiratory Society acceptability and reproducibility criteria; Results are in frequencies 
and Percentages. 
 Stringent Relaxed 
Acceptability Criteria   
BEV   
Young <=7-yrs-old 371(99.2%) 371(99.2%) 
Older >7-yrs-old 425(99.3%) 425(99.3%) 
BEV%FVC   
Young <=7-yrs-old 300 (80.2%)  
Older >7-yrs-old 361 (84.4%)  
FET   
Young <=7-yrs-old 11(2.9%) 208(56.6%) 
Older >7-yrs-old 20(4.7%) 321(75.0%) 
EOTV   
Young <=7-yrs-old 296(79.1%)  
Older >7-yrs-old 387(90.4%)  
Reproducibility Criteria   
DFVC   
Young <=7-yrs-old 348(93.1%) 311(83.2%) 
Older >7-yrs-old 412(96.3%) 367(85.8%) 
DFVC%   
Young <=7-yrs-old 236(63.1%)  
Older >7-yrs-old 297(69.4%)  
DFEV1   
Young <=7-yrs-old 365(97.6%) 326(87.2%) 
Older >7-yrs-old 415(97.0%) 375(87.6%) 
DFEV%   
Young <=7-yrs-old 232(62.0%)  
Older >7-yrs-old 282(65.9%)  
Stringent are criteria for adults:                          Relaxed are modified criteria for children: 
BEV<0.15L                                                                BEV<0.10L 
BEV%FVC<5%                                             
FET > 6s                                                                     FET>3s    
EOTV<0.05L                              
DFVC<200ml                                                              DFEV<100ml                    
DFVC%<5% 
DFEV1<200ml                                                           DEFV1<100ml 
DFEV1%<5% 
  494 
The acceptability criteria for start-of-test showed that the BEV% FVC was <5% in 82% of all 
children. At least 80% of the young age group (7-yrs-old and below) were able to reach this criterion 
and 84% of the older children (above 7-yrs-old) (Tables 5). The mean best BEV%FVC was 4 (+3%), 
range (1-60). There was no evidence of association between BEV% FVC and age, gender, height and 
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weight (Table 6). The BEV was <0.15 L in 99% of the children in both the younger age group and 
the older age group (Table 5). The mean best BEV was 0.05 (+0.05) L, range (0.01–1.12). There was 
a significant association of the BEV with height (Table 6). 
 
The acceptability criteria for end-of-test, show that the maximal FET was >6 s in 4% of all the 
children. 3% children in the younger age group and 5% in the older age group met this criterion 
(Table 5). The mean FET was 3.57 (+1.65) s, range (0.28–13.49). The FET was significantly related 
(positively) to height and negatively related to age (younger children) (Table 6). When FET was 
tested using the >3s criteria, 56% of the younger children, and 75% of the older children met this 
criterion. The EOTV was <0.05 L in 85% of the children. 79% children in the younger age group and 
90% in the older age group met this criterion (Table 5). The mean best EOTV was 0.04 (+0.10) L, 
range (0.00–0.76). There was a weak positive relationship of the EOTV with age (younger children), 
and a negative relationship with height (Table 6). 
 
The repeatability (reproducibility) criteria show that the absolute difference between the two highest 
FVC (DFVC), was <200 mL in 95% of the children. There were 93% children in the younger age 
group and 96% in the older age group that met this criterion (Table 5). The mean DFVC was 0.60 
(+0.90) L, range (0–1.48). There was a weak, although significant relationship of the DFVC with 
only the male gender (Table 6). The relative difference between two highest FVC (DFVC%) <5% 
was met by 66% of children (Table 5). Mean DFVC % was 5.14 (+ 6.14%), range (0–58.9). 69% of 
the children in the older age group reached the criterion and 63% in the younger age group.  There 
was a weak, but significant relationship of DFVC % with height (Table 6). 
 
The absolute difference between two highest FEV1 (DFEV1) was <200 mL in 97% of all children. 
98% patients in the younger age group and 97% in the older age group met this criterion (Table 5). 
The mean DFEV1 was 0.05 (+0.06) L, range (0-0.65). The DFEV1 was not significantly related to all 
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the anthropometry measures (Table 6). The relative difference between two highest FEV1 
(DFEV1%) was <5% in 64% of the children (Table 5). The mean DFEV1 % was 5 (+5%), 95% C.I. 
(0–46).  There was also no significant relationship between DFEV1% and anthropometry measures 
(Table 6). 
 
Table 6 Association between anthropometry measures and indices from the “best manoeuvre” and 
manoeuvres with the highest FEV and FVC, estimated by odds ratios (OR) and 95% confidence 
intervals 
 BEV%F
VC 
BEV, L FET, s EOTV, 
L 
DFVC DFVC
%              
DFEV1 DFEV1 
%          
Age: 
Older 
Referenc
e 
Referenc
e 
Referenc
e 
Referenc
e 
Referenc
e 
Referenc
e 
Referenc
e 
Referenc
e 
        
Young 
1.00(1.0
0-1.01) 
1.00(0.9
9-1.01) 
0.50(0.4
0-0.62) 
1.03(1.0
1-1.04) 
1.01(0.9
9-1.02) 
1.01(1.0
0-1.02) 
1.00(0.9
9-1.01) 
1.01(1.0
0-1.01) 
Gender 
Female 
Referenc
e 
Referenc
e 
Referenc
e 
Referenc
e 
Referenc
e 
Referenc
e 
Referenc
e 
Referenc
e 
          
Male 
1.00(0.9
9-1.00) 
1.00(1.0
0-1.01) 
1.23(1.0
0-1.54) 
1.00(0.9
9-1.01) 
1.02(1.0
1-1.03) 
1.01(1.0
0-1.02) 
1.01(1.0
0-1.02) 
1.01(1.0
0-1.02) 
Height  
0.98(0.9
5-1.02) 
1.08(1.0
2-1.15) 
326.37(5
3.47-
1992.28) 
0.81(0.7
2-0.90) 
0.95(0.8
6-1.05) 
0.88(0.8
2-0.94) 
1.06(0.9
9-1.13) 
0.96(0.9
0-1.02) 
Weight 1.00(1.0
0-1.00) 
1.00(1.0
0-1.00) 
1.14(1.0
9-1.18) 
1.00(0.9
9-1.00) 
1.00(1.0
0-1.00) 
1.00(1.0
0-1.00) 
1.00(1.0
0-1.00) 
1.00(1.0
0-1.00)  
 
4. Discussion 
The results show that most children were able to perform acceptable flow/volume manoeuvres 
according to the ATS and ERS acceptability and reproducibility criteria. Younger children, however, 
proved to have a challenge meeting the acceptability criteria but not the reproducibility criteria. Good 
quality spirometry is still not easily achievable by children even with the presence of modified 
quality criteria. Literature seems to suggest lowering the already lowered quality standards in order 
increase the number of children meeting the standards (Arets et al, 2001; Tomalak et al, 2008), but 
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this may have implications clinically. 
 
This study found that most children had acceptable 1
st
 manoeuvres but as more manoeuvres were 
performed acceptance rates decreased. This is in contrast with findings by Arets et al (2001), which 
suggested that, several attempts could improve skills and results for inexperienced children. 
Inexperienced children should familiarize themselves with spirometry procedures, especially during 
their ﬁrst test attempt to ensure adaptability and positive experience from it, which is necessary for 
good compliance and performance in subsequent tests (Arets et al, 2001). 
 
Also, children with an unacceptable 1
st
 manoeuvre also failed the second and the 3
rd
 subsequent 
manoeuvres. This means that children who fail the 1
st
 manoeuvre are most likely to also fail the 
following manoeuvres and it is understandable considering that the quality of all the failed 1
st
 
manoeuvres was F. Unaccepted manoeuvres were correlated with age (younger age group) and 
height. This shows how difficult it is to perform acceptable spirometry in young children, which is 
consistent to findings by a retrospective study assessing the adherence of flow-volume measurements 
to ATS/ERS 2005 standards in children younger than 10 years of age (Tomalak et al, 2008). The 
study found that children aged >6 years had lower cooperation levels, which went only up to 50%, 
despite specific techniques developed to aid performance (Tomalak et al, 2008). Even for the 
children with an accepted first manoeuvre, some failed both the 2
nd
 and the 3
rd
 subsequent 
manoeuvres, as they started off with poor quality manoeuvres (first manoeuvres were grade D). 
 
The second set of our findings was that most of the studied children could meet the current start-of-
test criteria, which is the most important phase of the manoeuvre (the maximally deep breath), 
requiring the most emphasis (Enright, 2003). The BEV appears to be the most appropriate start-of-
test criterion because of its independence to age and height (Arets et al, 2001). Arets et al (2001) 
found comparable results, which showed that with the guidance of a well-trained technician, most 
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children can achieve this criterion. Although, they studied children with extensive experience in lung 
function testing, 95% children aged <15 years met the BEV<0.15 L criterion. In the present study, 
99% of all children, although inexperienced, met both the BEV<0.15 L and the ERS criterion of 
BEV<0.10 L. Height and weight were positive, but weakly correlated with BEV and not correlated 
with BEV%FVC. This can be explained by the rise in FVC during the spontaneous growth of 
children (Arets et al, 2001).  
 
Moreover, the end-of-test criteria still proves to be far more difficult to meet for children and if this is 
not met (i.e. exhalation is not complete), the FVC will be underestimated leading to it being 
misinterpreted (i.e. misdiagnosing of patients as suffering from lung restriction, when they actually 
have normal lung volumes (Enright, 2003).  The FET criteria of >6s required by the ATS (Enright et 
al, 2011), was only met by a few children, yet it’s necessary for volume/ time curve without an 
obvious plateau in the display. Arets et al (2001), found that only 9% and 13% of children <8 years 
and 8-11 years old respectively, met the >6s criterion. They discovered that only 36% of the 
adolescents (aged >15 years) met this criteria, implying that older children also fails to forcefully 
exhale during >6s. The current study found that only 5% of the eldest group and 3% for the younger 
group expired beyond 6s, which is consistent with Arets et al (2001) that this criterion is unsuitable 
for use in paediatric practice.  
 
When FET was adjusted to >3s, as per the recommendations of the newest ATS/ERS for children 
aged > 10 years old (Beydon et al, 2007), still more children could not meet this criteria. In such 
cases the ATS, therefore, recommends that shorter FET be accepted in children, although these fails 
to be more specific (ATS, 1987 update). Tomalak et al, (2008), also found the current time of forced 
expiration >3 as too restrictive, and only 23.9% children in their study met this criteria. They 
proposed the development of specific standards for children. The EOTV was <0.05 L was 79% in the 
younger children and 90% for the older children.  
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Thirdly, when the absolute difference in FVC or FEV1, as proposed by the ATS, was taken as a 
criterion of reproducibility, this was easily met by most children, even the younger ones.  
 
Repeatability criteria using absolute differences for both FVC and FEV1 were significantly 
influenced by sex and weight for FEV1. This contradicts with Arets et al (2001), who found that 
these were signiﬁcantly inﬂuenced by age and height. The proportion of children decreased when 
relative criteria for repeatability was used. Relative criteria showed dependency upon height and 
weight instead of age. The ERS mentions that criteria using the relative difference (Quanjer et al, 
1993) are more appropriate in paediatric practice as they are not associated with either height or age. 
However, results from this study showed that most criteria depended upon height and weight instead 
of age. The 5% difference criteria were reached by 66% and 64% of children for FVC and FEV1, 
respectively. The current 5% criteria, when applied in this study seemed to be less useful in 
childhood than the absolute criterion of 100 or 200ml, opposing findings by Arets et al (2001). 
 
Lastly, the cross-sectional nature of this study; involving children inexperienced with lung function 
testing was the major limitations of this study. Spirometry and associations were also measured only 
at one point in time in participants homestead during the course of the study. A longitudinal design 
could produce more accurate results by enabling repeated measures of the outcomes and ensure 
enough chances for children to get experience and attain necessary skills for lung function testing. 
This design could also enable the investigation of other important predictors of quality which were 
not included in this study. The hospital setting would have been more appropriate and preferred for 
this study than home setting. 
 
5. Conclusion 
 This study has provided evidence that children fails to reach the goals of all ATS/ERS criteria. 
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Although, most children do produce acceptable manoeuvres, with the modified criteria, however the 
quality remains poor. Literature proposes further modification of the already lowered quality 
standards; however, not much thought has been given to the implications of this clinically. The 
concern would be if it’s still worthwhile to use spirometry in young children. Also, in order to 
determine whether experience could improve the quality of spirometry in this population, 
longitudinal studies involving repeated spirometry measurements are needed for lung function testing 
studies. 
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Legends of figures from the study 
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Figure 1. The proportion of acceptable manoeuvres decreased as more spirometry sessions were 
performed in children. An analysis of manoeuvre acceptability was conducted for the 3 “best 
manoeuvres”. Data showed that in the 1st manoeuvres, acceptability was at 77%, which declined by 
6% and 21% in the 2
nd
 and 3
rd
 manoeuvres.  
 
Figure 2. Spirometry quality indices were the least parameters used to determine acceptability of 
manoeuvres. A regression analysis was conducted to sow associations between spirometry indices 
and acceptability. Data showed a no association for BEV, EOTV was too small to be calculated and 
FET shows positive association (ORs: 0, excluded and 1.63).   
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Table 7 Definitions 
 Spirometry values  
FVC Forced vital capacity; the total volume of air that can be exhaled during a maximal 
forced expiration effort. 
FEV1 Forced expiratory volume in one second; the volume of air exhaled in the first second 
under force after a maximal inhalation. 
FEV1/ FVC 
ratio 
The percentage of the FVC expired in one second. 
FET Forced expiratory time is the total time it takes for a patient to complete their 
exhalation in a FVC manoeuvre. 
FEF25-75% Forced expiratory flow over the middle one half of the FVC; the average flow from 
the point at which 25 per cent of the FVC has been exhaled to the point at which 75 
per cent of the FVC has been exhaled. 
VC Vital capacity; the largest volume measured on complete exhalation after full 
inspiration. 
BEV backward extrapolated volume 
EOTV End of test volume 
BEV % 
FVC 
Backward extrapolated volume as percentage of forced vital capacity 
DFVC Absolute difference between two highest forced vital capacities 
DFVC % Percentage difference between two highest forced vital capacities 
DFEV1 Absolute difference between two highest forced expiratory volumes in one second 
DFEV1% Percentage difference between two highest forced expiratory volumes in one second 
Prod Predicted values  
Prod% Predicted%=Observed/predicted*100 
LLN Lower limit of normal. Lower predicted boundary/ range usually set at 5% above 
which normal value lies. It is calculated from the mean predicted value and the 
residual standard deviation. 
Manoeuvre Refers to a trace recording on  the spirometer when a client forcefully blast out air 
from a point of maximum inhalation to complete exhalation 
Best 
manoeuvre 
Manoeuvre with the largest FVC + FEV1 sum 
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Table 8 Relationships each spirometry index has on the levels of quality which is in Grades A, B, C, 
D and F 
 Spiro 
Indices 
Pre Post 
Quality 
Grade 
 Crude 
OR 
95% C. I Crude 
OR 
95% C. I 
 
 
 
 
 
 
 
 
Grade 
 
 
A 
Maneuver 1     
FVC 4.06  2.29-7.22 1.77  0.96-3.26 
FEV1 7.21  3.57-14.57 4.89  2.34-10.22 
FEV1/FVC 0.53  0.10-2.77 76.85 9.27-637.29 
FEF2575 1.71  1.26-2.31 2.62  1.92-3.58 
FEV6 4.85  2.69-8.74 2.24  1.18-4.26 
Vaux  4.06  2.29-7.22 1.77  0.96-3.26 
BEV 0.11  0.00-3.95 0.00 4.99e-08-0.02 
FET 1.50  1.35-1.66 1.14  1.02-1.28 
EOTV 1.17e-08 2.84e-11-  4.81e-06 0.00 0.00-0.08 
Maneuver 2     
FVC 5.35  2.96-  9.64 2.80  1.46-5.37 
FEV1 13.43  6.41-28.14 8.80  4.08-18.97 
FEV1/FVC 1.10  0.23-5.16 249.66 29.60-2105.41 
FEF2575 2.04  1.50-2.79 3.48  2.50-4.84 
FEV6 6.40  3.50-11.73 3.16  1.63-6.13 
VCmax 5.28  2.93-9.53 2.80  1.46-5.37 
BEV 0.02 0.00-6.20 0.10  0.00-51.52 
FET 1.40  1.28-1.54 1.16 1.03-1.29 
EOTV 8.37e-10 1.17e-12 -5.99e-07 0.00  3.57e-06-0.03 
Maneuver 3     
FVC 2.06  1.19-3.56 0.96  0.51-1.84 
FEV1 3.49  1.75-6.93 2.32 1.10-4.90 
FEV1/FVC 0.73 0.17-3.03 77.89 11.35-534.70 
FEF2575 1.41  1.05-1.89 2.44 1.78-3.34 
FEV6 2.51  1.41-4.45 1.02 0.53-1.94 
VCmax 2.03  1.17-3.52 0.99  0.52-1.89 
BEV 2.52e-06 3.23e-09 - 0.00 1.73e-08 2.17e-11-0.00 
FET 1.39 1.27-1.52 1.20 1.07-1.34 
EOTV 2.74e-08 2.19e-10-3.42e-06 7.65e-07 2.65e-09-0.00 
 
 
 
 
 
 
 
 
 
 
 
 
Maneuver1 OR 95% C. I OR 95% C. I 
FVC 0.44  0.16-1.22 0.34  0.11-1.11 
FEV1 0.60  0.18-1.98 0.34  0.09-1.26 
FEV1/FVC 18.17 0.56-591.35 1.81 0.04-75.85 
FEF2575 1.22 0.72-2.07 0.71 0.42-1.22 
FEV6 0.46 0.17-1.28 0.35 0.11-1.14 
VCmax 0.44  0.16-1.22 0.34 0.11-1.11 
BEV 0.00  2.88e-09 - 840.75 0.09 6.08e-07 - 
13662.08 
FET 0.89  0.76-1.05 0.94  0.77-1.15 
EOTV 0.13 0.00-4.80 0.00 9.16e-08 - 88.39   
Maneuver2     
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Grade 
 
 
B 
FVC 0.52  0.19-1.41 0.36 0.11-1.18 
FEV1 0.67 0.20-2.24 0.37  0.10-1.39 
FEV1/FVC 7.16 0.32-157.76 1.40 0.04-50.92 
FEF2575 1.20  0.70-2.04 0.77 0.45-1.33 
FEV6 0.55  0.20-1.50 0.37 0.11-1.21 
VCmax 0.52 0.19-1.42 0.36 0.11-1.18 
BEV 0.32  0.00 - 1430.94 6.18e-06 9.86e-13-38.71 
FET 0.97  0.84-1.12 0.88  0.72-1.08 
EOTV 0.01 0.00-1.14 0.06 0.00-30.76 
Maneuver3     
FVC 2.16 0.85-5.52 2.58 0.79-8.41 
FEV1 4.83 1.46-16.03 2.89 0.74-11.22 
FEV1/FVC 11.72 0.57-240.76 0.94 0.03-26.92 
FEF2575 1.83  1.09-3.07 0.96 0.56-1.64 
FEV6 2.45 0.90-6.65 2.59 0.79-8.47 
VCmax 2.18 0.86-5.57 2.61 0.80-8.52 
BEV 10.03 0.15-688.83 664.12 1.69-260292.5 
FET 0.79 0.68-0.93 0.87 0.71-1.06 
EOTV 0.82 0.08-8.16 3.68 0.33-41.73 
 
 
 
 
 
 
 
 
 
 
Grade 
 
 
C 
Maneuver1 OR 95% C. I OR 95% C. I 
FVC 0.79 0.27-2.29 1.86 0.63- 5.45 
FEV1 0.70 0.19-2.54 2.90 0.76- 11.13 
FEV1/FVC 0.34 0.02-7.01 3.58 0.06- 1.99.15 
FEF2575 0.81 0.45-1.45 1.18 0.69- 2.05 
FEV6 0.84 0.28-2.47 2.24 0.68- 7.43 
VCmax 0.79 0.27-2.29 1.86 0.63- 5.45 
BEV 2.52e-09 5.20e-17-0.12 0.01 1.37e-08 – 
3504.78 
FET 1.06 0.90-1.24 0.97 0.79 – 1.19 
EOTV 1.10e-07 1.56e-14-0.78 3.15e-14 1.55e-32 – 
64137.71 
Maneuver2     
FVC 0.28  0.09-0.83 0.67 0.20- 2.23 
FEV1 0.16 0.04-0.61 0.71 0.19- 2.76 
FEV1/FVC 0.32 0.02-5.24 1.28 0.03- 50.14 
FEF2575 0.47 0.26-0.85 0.72 0.41- 1.26 
FEV6 0.29 0.09-0.87 0.70 0.21- 2.34 
VCmax 0.28 0.09-0.84 0.67 0.20- 2.23 
BEV 7.55e-15 2.37e-23 - 2.41e-06 1.46e-06 1.11-13 – 19.30 
FET 0.99 0.84-1.15 1.06 0.87 – 1.28 
EOTV 0.00 4.97e-06-1.59 0.01 9.25e-07 – 74.89 
Maneuver 3     
FVC 0.56 0.19-1.63 1.41 0.42-4.70 
FEV1 0.46 0.12-1.70 1.33 0.33-5.27 
FEV1/FVC 0.67 0.05-9.62 0.47 0.02-12.71 
FEF2575 0.71 0.40-1.25 0.81 0.46-1.40 
FEV6 0.58 0.19-1.74 1.27 0.38-4.29 
VCmax 0.56 0.19-1.64 1.25 0.37-4.23 
BEV 0.31 0.00-1116.52 20.95 0.21-2140.91 
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FET 1.04 0.90-1.21 1.12 0.90-1.38 
EOTV 0.10 0.00-3.42 0.02 0.00-20.34 
 
 
 
 
 
 
 
 
 
 
 
 
Grade 
 
D 
Maneuver1 OR 95% C. I OR 95% C. I 
FVC 0.53 0.23-1.25 0.29 0.11- 0.77 
FEV1 0.65 0.24-1.79 0.34 0.12-1.03 
FEV1/FVC 11.44 0.65- 200.26 8.11 0.28-238.84 
FEF2575 1.08 0.69-1.69 0.89 0.57-1.38 
FEV6 0.56 0.24-1.32 0.29 0.11-0.78 
VCmax 0.53 0.23-1.25 0.29 0.11-0.77 
BEV 0.00 1.05e-09 – 18.96 0.02 5.63e-07 – 468.64 
FET 0.90 0.79 – 1.03 0.80 0.67- 0.95 
EOTV 0.08 0.00- 2.12 0.12 0.00-10.40 
Maneuver2     
FVC 0.94 0.41-2.16 0.34 0.13-0.89 
FEV1 0.39 0.14-1.08 0.21 0.07-0.64 
FEV1/FVC 0.04 0.00-0.30 0.32 0.02-5.08 
FEF2575 0.47 0.29-0.75 0.58 0.37-0.91 
FEV6 0.83 0.35-1.93 0.29 0.11-0.77 
VCmax 0.95 0.42-2.18 0.34 0.13-0.89 
BEV 0.51 0.00-277.64 213.29 0.08- 578042.6 
FET 1.04 0.92-1.17 0.90 0.76- 1.06 
EOTV 0.25 0.02-2.76 2.54 0.23-28.45 
Maneuver 3     
FVC 1.42 0.63-3.17 0.54 0.20-1.47 
FEV1 0.77 0.28-2.14 0.40 0.13-1.26 
FEV1/FVC 0.21 0.03-1.51 0.36 0.03-5.20 
FEF2575 0.66 0.42-1.03 0.62 0.39-0.98 
FEV6 1.12 0.48-2.63 0.55 0.20-1.49 
VCmax 1.43 0.64-3.20 0.55 0.20-1.48 
BEV 9.66 0.20-473.75 15.25 0.20-1178.59 
FET 1.03 0.92-1.17 0.90 0.76-1.06 
EOTV 1.49 0.26-8.57 1.70 0.16-18.27 
 
 
 
 
 
 
 
 
 
 
 
 
 
Grade 
 
 
 
Maneuver1 OR 95% C. I OR 95% C. I 
FVC 0.31 0.16-0.62 1.08 0.49-2.40 
FEV1 0.11 0.05-0.26 0.14 0.05-0.38 
FEV1/FVC 0.36 0.05-2.44 0.00 0.00-0.00 
FEF2575 0.43 0.29-0.62 0.22 0.14-0.33 
FEV6 0.23 0.11-0.46 0.70 0.30-1.64 
VCmax 0.31 0.16-0.62 1.08 0.49-2.40 
BEV 10317.54 10.17-1.05e+07 1.98+08 113682.7 – 
3.44e+1 
FET 0.62 0.55-0.69 0.97 0.84-1.12 
EOTV 7714152 152895.5- 3.89+08 11736.61 380.48 – 362038.1 
Maneuver2     
FVC 0.20 0.10 - 0.40 0.78 0.32-1.85 
FEV1 0.11 0.05 - 0.27 0.14 0.05-0.39 
FEV1/FVC 8.55 1.09 – 66.97 0.00 0.00 – 0.01 
FEF2575 0.70 0.49 – 1.01 0.22 0.14-0.34 
FEV6 0.16 0.08 – 0.34 0.69 0.29-1.67 
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F VCmax 0.20 0.10 - 0.41 0.78 0.32-1.85 
BEV 44519.83 41.33 – 4.80e+07 1013.07 0.65- 1582052 
FET 0.57 0.51 – 0.65 0.86 0.74-1.00 
EOTV 5520587 184883.3 – 
1.65e+08 
1038.99 66.16- 16317.61 
Maneuver 3     
FVC 0.21 0.10-0.43 0.85 0.34 – 2.09 
FEV1 0.11 0.04-0.26 0.19 0.06 – 0.54 
FEV1/FVC 2.34 0.37- 14.65 0.00 0.00 – 0.03 
FEF2575 0.67 0.47 – 0.96 0.30 0.19 – 0.48 
FEV6 0.17 0.08-0.36 0.80 0.32 – 1.98 
VCmax 0.21 0.10 – 0.43 0.86 0.35 – 2.11 
BEV 160.01 1.48- 17319.51 42.69 0.48 – 3762.049 
FET 0.62 0.55 – 0.70 0.79 0.68 – 0.93 
EOTV 8587.18 1102.27 – 66898.1 2570.73 172.15 – 38388.68 
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Table 9 Relationships of spirometry indices with acceptability outcomes in both the pre and post 
bronchodilator tests 
 Pre Post 
Risk factor Crude OR 95% C. I Crude OR 95% C. I 
Maneuver1     
FVC 3.21 1.63-6.33 0.92 0.42-2.04 
FEV1 8.9 3.85-20.93 7.01 2.66-18.9 
FEV1/FVC 2.78 0.41-18.71 2971.71 248.52 -35534.68 
FEF2575 2.34 1.61-3.40 4.65 3.03-7.13 
FEV6 4.37 2.17-8.79 1.43 0.61-3.33 
VCmax 3.21 1.63-6.33 0.92 0.42-2.04 
BEV 0.00 9.55e-08- 0.10 5.05e-09 2.90e-12-8.80e-06 
FET 1.63 1.44-1.83 1.03 0.89-1.19 
EOTV 1.30e-07 2.57e-09 -6.54e-06 0.00 2.76e-06-0.00 
Maneuver2     
FVC 2.67 1.43-4.98 1.01 0.47-2.16 
FEV1 5.03 2.32-10.89 4.38 1.82-10.54 
FEV1/FVC 0.52 0.09-3.00 1144.20 115.64-11321.2 
FEF2575 1.49 1.06-2.08 3.81 2.57-5.64 
FEV6 3.37 1.77-6.41 1.20 0.56-2.60 
VCmax 2.64 1.41-4.94 1.01 0.47-2.16 
BEV 8.24e-08 6.11e-11-0.00 8.43e-06 4.65e-09-  0.02 
FET 1.57 1.41-1.74 1.23 1.07-1.41 
EOTV 7.78e-10 5.13e-12 - 1.18e-07 0.00 1.18e-07-0.00 
Maneuver3     
FVC 1.37 0.79-2.38 0.61 0.31-1.21 
FEV1 1.70 0.86-3.37 1.64 0.75-3.56 
FEV1/FVC 0.27 0.06-1.21 1.55.76 22.02-1101.73 
FEF2575 1.04 0.77-1.39 2.46 1.77-3.42 
FEV6 1.65 0.93-2.94) 0.63 0.32-1.24 
VCmax 1.36 0.78-2.35) 0.60 0.31-1.19 
BEV 7.83e-10 5.24e-13 - 1.17e-06) 2.52e-10 2.37e-13-2.68e-07 
FET 1.53 1.39-1.68 1.24 1.10-1.40 
EOTV 1.10e-09 6.49e-12- 1.86e-07 2.86e-08 6.48e-11-  0.00 
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 C.         
  D.   
Figure 3 (A, B, C and D) Box plots showing the distribution of each spirometry index in the 1
st
 
manoeuvre by acceptance outcome and quality grades.  
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C.  
D.  
Figure 4 (A, B, C and D) Histograms showing distribution of Age, weight and height by acceptance 
outcomes and quality grades 
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APPENDIX D RECORD OF SEARCH STRATEGY 
Topic: the quality and variation of spirometry reads to measure lung function in children in 
sub Saharan Africa 
Population/Problem:  children  
Intervention/Issue: good quality spirometry 
Comparison:  
Outcome/Evaluation: lung function diagnosis 
Main concepts/keywords/synonyms: quality, variations, lung function tests, children, sub 
Saharan Africa 
Searches were conducted in two databases to identify recent publications – PubMed and 
Google scholar. 
  Limits: Language English 
    Time frame: PubMed (up-to-2019) & Google scholar (2015-2019)  
Abstracts of identified documents were read and full text of relevant documents was 
retrieved for inclusion in the review. Reference lists of retrieved documents were also 
searched to identify additional publications. A summary of the database searches is set out 
below. 
Database 
searched 
Search terms Results Sources 
used 
PubMed Set 1. 
Child [Mesh] OR Child, Preschool [Mesh} OR Child 
OR Children 
2341515 
Set 2. 
Spirometry"[Mesh]) OR (Spirometry OR Spirometry 234188 
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tests OR respiratory function tests) 
Set 3. 
Quality Control"[Mesh]) OR "Quality Assurance, 
Health Care"[Mesh]) OR "Quality 
Improvement"[Mesh]) OR (Quality OR variations 
OR quality control OR quality improvement OR 
quality assurance) 
1525608 
Set 4. 
(lung function OR respiratory function 
445681 
Set 5. 
((Deprived Countries[Text Word] OR Deprived 
Population[Text Word] OR Deprived 
Populations[Text Word] OR Developing 
Countries[Text Word] OR Developing Country[Text 
Word] OR Developing Economies[Text Word] OR 
Developing Economy[Text Word] OR Developing 
Nation[Text Word] OR Developing Nations[Text 
Word] OR Developing Population[Text Word] OR 
Developing Populations[Text Word] OR 
Developing World[Text Word] OR LAMI 
Countries[Text Word] OR LAMI Country[Text 
Word] OR Less Developed Countries[Text Word] 
OR Less Developed Country[Text Word] OR Less 
Developed Economies [Text Word] OR Less 
Developed Nation[Text Word] OR Less Developed 
Nations[Text Word] OR Less Developed 
World[Text Word] OR Lesser Developed 
Countries[Text Word] OR Lesser Developed 
Nations[Text Word] OR LMIC[Text Word] OR 
LMICS[Text Word] OR Low GDP[Text Word] OR 
Low GNP[Text Word] OR Low Gross 
Domestic[Text Word] OR Low Gross National[Text 
Word] OR Low Income Countries[Text Word] OR 
Low Income Country[Text Word] OR Low Income 
Economies [Text Word] OR Low Income 
Economy[Text Word] OR Low Income Nations[Text 
Word] OR Low Income Population[Text Word] OR 
Low Income Populations[Text Word] OR Lower 
GDP[Text Word] OR lower gross domestic[Text 
Word] OR Lower Income Countries[Text Word] OR 
Lower Income Country[Text Word] OR Lower 
Income Nations[Text Word] OR Lower Income 
Population[Text Word] OR Lower Income 
Populations[Text Word] OR Middle Income 
Countries[Text Word] OR Middle Income 
Country[Text Word] OR Middle Income Economies 
[Text Word] OR Middle Income Nation[Text Word] 
OR Middle Income Nations[Text Word] OR Middle 
Income Population[Text Word] OR Middle Income 
Populations[Text Word] OR Poor Countries[Text 
Word] OR Poor Country[Text Word] OR Poor 
1373466 
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Economies [Text Word] OR Poor Economy[Text 
Word] OR Poor Nation[Text Word] OR Poor 
Nations[Text Word] OR Poor Population[Text 
Word] OR Poor Populations[Text Word] OR poor 
world[Text Word] OR Poorer Countries[Text Word] 
OR Poorer Economies [Text Word] OR Poorer 
Economy[Text Word] OR Poorer Nations[Text 
Word] OR Poorer Population[Text Word] OR 
Poorer Populations[Text Word] OR Third 
World[Text Word] OR Transitional Countries[Text 
Word] OR Transitional Country[Text Word] OR 
Transitional Economies[Text Word] OR 
Transitional Economy[Text Word] OR Under 
Developed Countries[Text Word] OR Under 
Developed Country[Text Word] OR under 
developed nations[Text Word] OR Under 
Developed World[Text Word] OR Under Served 
Population[Text Word] OR Under Served 
Populations[Text Word] OR Underdeveloped 
Countries[Text Word] OR Underdeveloped 
Country[Text Word] OR underdeveloped 
economies[Text Word] OR underdeveloped 
nations[Text Word] OR underdeveloped 
population[Text Word] OR Underdeveloped 
World[Text Word] OR Underserved Countries[Text 
Word] OR Underserved Nations[Text Word] OR 
Underserved Population[Text Word] OR 
Underserved Populations[Text Word]))) OR 
((Afghanistan[Text Word] OR Albania[Text Word] 
OR Algeria[Text Word] OR American Samoa[Text 
Word] OR Angola[Text Word] OR Armenia[Text 
Word] OR Azerbaijan[Text Word] OR 
Bangladesh[Text Word] OR Belarus[Text Word] 
OR Byelarus[Text Word] OR Belorussia[Text 
Word] OR Belize[Text Word] OR Benin[Text Word] 
OR Bhutan[Text Word] OR Bolivia[Text Word] OR 
Bosnia[Text Word] OR Botswana[Text Word] OR 
Brazil[Text Word] OR Bulgaria[Text Word] OR 
Burma[Text Word] OR Burkina Faso[Text Word] 
OR Burundi[Text Word] OR Cabo Verde[Text 
Word] OR Cape Verde[Text Word] OR 
Cambodia[Text Word] OR Cameroon[Text Word] 
OR Central African Republic[Text Word] OR 
Chad[Text Word] OR China[Text Word] OR 
Colombia[Text Word] OR Comoros[Text Word] OR 
Comores[Text Word] OR Comoro[Text Word] OR 
Congo[Text Word] OR Costa Rica[Text Word] OR 
Côte d'Ivoire[Text Word] OR Cuba[Text Word] OR 
Djibouti[Text Word] OR Dominica[Text Word] OR 
Dominican Republic[Text Word] OR Ecuador[Text 
Word] OR Egypt[Text Word] OR El Salvador[Text 
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Word] OR Equatorial Guinea[Text Word] OR 
Eritrea[Text Word] OR Ethiopia[Text Word] OR 
Fiji[Text Word] OR Gabon[Text Word] OR 
Gambia[Text Word] OR Gaza[Text Word] OR 
Georgia[Text Word] OR Georgia Republic[Text 
Word] OR Ghana[Text Word] OR Grenada[Text 
Word] OR Grenadines[Text Word] OR 
Guatemala[Text Word] OR Guinea[Text Word] OR 
Guinea- Bissau[Text Word] OR Guyana[Text 
Word] OR Haiti[Text Word] OR Herzegovina[Text 
Word] OR Hercegovina[Text Word] OR 
Honduras[Text Word] OR India[Text Word] OR 
Indonesia[Text Word] OR Iran[Text Word] OR 
Iraq[Text Word] OR Jamaica[Text Word] OR 
Jordan[Text Word] OR Kazakhstan[Text Word] OR 
Kenya[Text Word] OR Kiribati[Text Word] OR 
Democratic People‘s Republic of Korea[Text Word] 
OR Kosovo[Text Word] OR Kyrgyz[Text Word] OR 
Kirghizia[Text Word] OR Kirghiz[Text Word] OR 
Kyrgyzstan[Text Word] OR Lao PDR[Text Word] 
OR Laos[Text Word] OR Lebanon[Text Word] OR 
Lesotho[Text Word] OR Liberia[Text Word] OR 
Libya[Text Word] OR Macedonia[Text Word] OR 
Madagascar[Text Word] OR Malawi[Text Word] 
OR Malay[Text Word] OR Malaya[Text Word] OR 
Malaysia[Text Word] OR Maldives[Text Word] OR 
Mali[Text Word] OR Marshall Islands[Text Word] 
OR Mauritania[Text Word] OR Mauritius[Text 
Word] OR Mexico[Text Word] OR Micronesia[Text 
Word] OR Moldova[Text Word] OR Mongolia[Text 
Word] OR Montenegro[Text Word] OR 
Morocco[Text Word] OR Mozambique[Text Word] 
OR Myanmar[Text Word] OR Namibia[Text Word] 
OR Nepal[Text Word] OR Nicaragua[Text Word] 
OR Niger[Text Word] OR Nigeria [Text Word] OR 
Pakistan [Text Word] OR Palau[Text Word] OR 
Panama[Text Word] OR Papua New Guinea[Text 
Word] OR Paraguay[Text Word] OR Peru [Text 
Word] OR Philippines[Text Word] OR Principe[Text 
Word] OR Romania[Text Word] OR Ruanda[Text 
Word] OR Rwanda[Text Word] OR Samoa[Text 
Word] OR Sao Tome[Text Word] OR Senegal[Text 
Word] OR Serbia[Text Word] OR Sierra 
Leone[Text Word] OR Solomon Islands[Text Word] 
OR Somalia[Text Word] OR South Africa[Text 
Word] OR South Sudan[Text Word] OR Sri 
Lanka[Text Word] OR St Lucia[Text Word] OR St 
Vincent[Text Word] OR Sudan[Text Word] OR 
Surinam[Text Word] OR Suriname[Text Word] OR 
Swaziland[Text Word] OR Syria[Text Word] OR 
Syrian Arab Republic[Text Word] OR 
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Tajikistan[Text Word] OR Tadzhikistan[Text Word] 
OR Tajikistan[Text Word] OR Tadzhik[Text Word] 
OR Tanzania[Text Word] OR Thailand[Text Word] 
OR Timor[Text Word] OR Togo[Text Word] OR 
Tonga[Text Word] OR Tunisia[Text Word] OR 
Turkey[Text Word] OR Turkmen[Text Word] OR 
Turkmenistan[Text Word] OR Tuvalu[Text Word] 
OR Uganda[Text Word] OR Ukraine[Text Word] 
OR Uzbek[Text Word] OR Uzbekistan[Text Word] 
OR Vanuatu[Text Word] OR Venezuela[Text Word] 
OR Vietnam[Text Word] OR West Bank[Text Word] 
OR Yemen[Text Word] OR Zambia[Text Word] OR 
Zimbabwe[Text Word])) 
1 AND 2 AND 3 AND 4 AND 5 85 
Googlescholar Googlescholar: "Chronic respiratory diseases" 
AND estimates AND children AND sub saharan 
Africa 
31600 
Since 2015 (chose the first 50) 12900 
Health Sciences Library, UCT 
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APPENDIX E Paediatrics Author Guidelines 
(http://www.aappublications.org/content/pediatrics-author-guidelines#submitting) 
Paediatrics Author Guidelines 
Paediatrics is the official peer-reviewed journal of the American Academy of Paediatrics. 
Paediatrics publishes original research, clinical observations, and special feature articles in 
the field of paediatrics, as broadly defined. Contributions pertinent to paediatrics also 
include related fields such as nutrition, surgery, dentistry, public health, child health 
services, human genetics, basic sciences, psychology, psychiatry, education, sociology, 
and nursing. 
Paediatrics considers unsolicited manuscripts in the following categories: reports of 
original research, particularly clinical research; review articles; special articles; and case 
reports. When preparing a manuscript for Paediatrics, authors must first determine the 
manuscript type and then prepare the manuscript according to the specific instructions 
below. 
The digital edition of Paediatrics is the journal of record. Some accepted article types 
may also be presented in full in print, in addition to the digital edition of Paediatrics. 
Contents 
Introduction 
 Journal Style
 Reuse of Data Sets
 Data Sharing
Manuscript Preparation 
 Formatting Requirements
 Title Page
 Contributors' Statement Page
 Word Count
 Figures, Tables, and Supplementary Material
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Article Type 
 Regular Article
Journal Style 
All aspects of the manuscript, including the formatting of tables, illustrations, and 
references and grammar, punctuation, usage, and scientific writing style, should be 
prepared according to the most current AMA Manual of Style 
(http://www.amamanualofstyle.com).1 
Author Listing 
All authors‘ names should be listed in their entirety, and should include 
institutional/professional affiliations and degrees held. 
Authoring Groups 
 If you choose to include an organization, committee, team, or any other group as part of 
your author list, you must include the names of the individuals as part of the 
Acknowledgments section of your manuscript. This section should appear after the main 
text prior to your References section. (If your Acknowledgments include both group 
members and other persons/organizations that are not in that group, you should instead 
list the group members in a separate appendix to avoid confusion.) The terms ―for‖ or ―on 
behalf of‖ must also be used when referencing the authoring group in the by-line. 
Titles 
Paediatrics generally follows the guidelines of the AMA Manual of Style for titles. Titles 
should be concise and informative, containing the key topics of the work. Declarative 
sentences are discouraged as they tend to overemphasize a conclusion, as are 
questions, which are more appropriate for editorials and commentaries. Subtitles, if used, 
should expand on the title; however, the title should be able to stand on its own. It is 
appropriate to include the study design (―Randomized Controlled Trial‖; ―Prospective 
Cohort Study‖, etc.) in subtitles. The location of a study should be included only when the 
results are unique to that location and not generalizable. Abbreviations and acronyms 
should be avoided. The full title will appear on the article, the inside table of contents, 
and in MEDLINE. Full titles are limited to 97 characters, including spaces. Short titles 
must be provided as well and are limited to 55 characters, including spaces. Short titles 
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may appear on the cover of the journal as space permits in any given issue. 
Abbreviations 
List and define abbreviations on the Title Page. Unusual abbreviations should be avoided. 
All terms to be abbreviated in the text should also be spelled out at first mention, followed 
by the abbreviation in parentheses. The abbreviation may appear in the text thereafter. 
Abbreviations may be used in the abstract if they occur 3 or more times in the abstract. 
Abbreviations should be avoided in tables and figures; if used they should be redefined in 
footnotes. 
Units of Measure 
Like many US-based journals, Paediatrics uses a combination of System International 
(SI)2,3 and conventional units. Please see the AMA Manual of Style for details. 
Proprietary Products 
Authors should use non-proprietary names of drugs or devices unless mention of a trade 
name is pertinent to the discussion. If a proprietary product is cited, the name and location 
of the manufacturer must also be included. 
References 
 Authors are responsible for the accuracy of references. Citations should be numbered 
in the order in which they appear in the text. Reference style should follow that of the 
AMA Manual of Style, current edition. Abbreviated journal names should reflect the style 
of Index Medicus. Visit: http://www.nlm.nih.gov/tsd/serials/lji.html 
References 
1. Iverson C, Christiansen S, Flanagin A, et al. AMA Manual of Style. 10th Ed. New York,
NY: Oxford University Press; 2007.
2. Lundberg GD. SI unit implementation: the next step. JAMA. 1988; 260:73-76.
3. System International conversion factors for frequently used laboratory components.
JAMA. 1991; 266:45-47.
Reuse of Data Sets 
If a manuscript uses the same or similar data contained in previously published articles, the 
authors must state this in the cover letter (and provide citations to the related or possibly 
duplicative materials). 
If a separate manuscript by the same authors using the same data set is under review or 
accepted but not yet published in another journal, the authors must state this in the cover 
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letter and provide enough information to assure that the manuscript submitted to 
Paediatrics is not duplicative. 
Data Sharing 
The International Committee of Medical Journal Editors (ICMJE) requires ICMJE journals 
to include data sharing statements in articles that report results of clinical trials. 
Data sharing statements must include: 
• Whether DE identified participant data (including data dictionaries) will be shared
• The data that will be shared
• Whether additional documents will be made available
• The start and end dates of data availability
• Access criteria
• How the data will be made available
The data sharing statement must be included on the title page of your manuscript and 
entered into the section provided in the manuscript management system. 
If you will not be sharing your data, insert the following statement on your title page 
and in the manuscript submission system. 
Data Sharing Statement: DE identified individual participant data will not be made available. 
If you will be sharing your data, refer to the table in the data sharing section of the ICMJE 
clinical trials page for examples of how to incorporate the required information into your 
statement, and refer to the example below. 
Data Sharing Statement: DE identified individual participant data (including data 
dictionaries) will be made available, in addition to study protocols, the statistical analysis 
plan, and the informed consent form. The data will be made available upon publication to 
researchers who provide a methodologically sound proposal for use in achieving the goals 
of the approved proposal. Proposals should be submitted to ____________ [INSERT 
EMAIL ADDRESS OR OTHER CONTACT INFORMATION]. 
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Formatting Requirements 
All submissions must adhere to the following format: 
• Times New Roman font, size 12, black
• Title Page, Contributors' Statement Page, Abstract,
Acknowledgments, and References should be single-
spaced
• Only the Main Body Text should be double-spaced
• Main Submission Document as Microsoft Word or RTF file (no PDFs)
• Do not include page headers, footers, or line numbers in new submissions.
• Do not include footnotes within the manuscript body. Footnotes are allowed only in
tables/figures.
Refer to the ―Article Types‖ section for specific guidelines on preparing a manuscript in 
each category. Note in particular the requirements regarding abstracts for different 
categories of article. 
Title Page 
The ―title page‖ should appear first in your manuscript document, and depending on the 
individual needs of a paper may encompass more than one page. 
Title pages for all submissions must include the following items (as shown in the sample 
Title Page):  
1. Title (97 characters [including spaces] or fewer)
2. Author listing. Full names for all authors, including degrees, and institutional/professional
affiliations. These affiliations should list the institution where the research presented in
the article took place; if the affiliation has changed, add a note indicating the additional
affiliation. Paediatrics permits a statement of equal contribution for two first authors only;
on the title page, includes asterisks by each name and a statement that reads: *
Contributed equally as co-first authors.
3. Corresponding Author. Contact information for the Corresponding Author (including:
name, address, telephone, and e-mail). Again, note that the affiliation should list the
institution where the research presented in the article took place; if the affiliation has
changed, add a note indicating the additional affiliation.
4. Short title (55 characters [including spaces] or fewer). Please note: the short title may be
used on the cover of the print edition.
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5. Financial Disclosure Statement for all authors. Disclose any financial relationships that
could be broadly relevant to the work. If none say ―Financial Disclosure: The authors
have no financial relationships relevant to this article to disclose.‖
6. Funding source. Research or project support, including internal funding, should be listed
here; if the project was done with no specific support, please note that here. Technical
and other assistance should be identified in Acknowledgments. If your funding body has
open access requirements, please contact the Editorial Office prior to submission.
Paediatrics has a 12 month embargo on articles (followed by a 4 year open access
period) and does not allow articles to be opened for Creative Commons or similar
licenses.
7. Conflict of Interest Statement for all authors. If none say ―Potential Conflicts of Interest:
The authors have no conflicts of interest relevant to this article to disclose.‖
8. If applicable, Clinical Trial registry name, registration number, and data sharing
statement. We adhere to ICMJE guidelines, which require that all trials must be
registered with ClinicalTrials.gov or any other WHO Primary registry. All articles
reporting results of clinical trials must also include the Data Sharing Statement.
9. Abbreviations. List and define abbreviations used in the text. If none say "Abbreviations:
none".
0. Table of Contents Summary. All articles with abstracts require this summary. This brief
summary is limited
To 25 words. For accepted manuscripts, this will appear under the author names in the
table of contents to give the reader a brief insight into what the article is about. It should
entice the reader to read the full article. For example: "Through linkage of state Medicaid
and Child Protective Services databases, this study captures similarities and differences
in health care expenditures based on a history of child maltreatment."
1. For Regular Article submissions, include both the ―What‘s Known on This Subject" and
the "What This Study Adds‖ summaries (see below under Regular Article type for
description). These are not needed for any other article type.
If a title page does not include all of the above items, the submission may be returned to 
the authors for completion.  
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Contributors' Statement Page 
All submissions (excluding Commentaries) must contain a Contributors‘ Statement Page, 
directly following the Title Page(s) and in the specific format described below. Manuscripts 
lacking a properly formatted Contributors' Statement Page will be returned to the authors 
for correction. 
All persons designated as authors must qualify for authorship (see "Publication Ethics" 
above), and all those who qualify should be listed. Each author should have participated 
sufficiently in the work to take public responsibility for appropriate portions of the content. 
The Contributors' Statement Page lists the authors and specifies the contribution(s) made 
by each individual. If multiple individuals have identical contributions they may be listed 
together; do not list an author more than once. 
You must follow the required format when creating your Contributors‘ Statement Page or 
your manuscript will be returned for correction. 
• Each author should only appear once.
• Use names, not initials.
• If multiple authors have identical contributions, you can list them in the same sentence;
otherwise, list each author separately.
• Conclude your statement by confirming that: All authors approved the final manuscript as
submitted and agree to be accountable for all aspects of the work.
Sample Contributors' Statement: 
Dr Smith and Prof Jones conceptualized and designed the study, drafted the initial 
manuscript, and reviewed and revised the manuscript. 
Drs Brown, Grey, and Black and Ms Johnson designed the data collection instruments, 
collected data, carried out the initial analyses, and reviewed and revised the manuscript. 
Dr Green conceptualized and designed the study, coordinated and supervised data 
collection, and critically reviewed the manuscript for important intellectual content. 
All authors approved the final manuscript as submitted and agree to be accountable for all 
aspects of the work. 
Note: Contributors who do not meet the criteria for authorship (such as persons who 
helped recruit patients for the study, or professional editors) should be listed in an 
Acknowledgments section placed after the manuscript‘s conclusion and before the 
References section. Because readers may infer their endorsement of the data and 
conclusions, these persons must give written permission to be acknowledged. These 
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permissions do not need to be submitted with the manuscript unless requested by the 
editors. 
Word Count 
To determine article length, count the body of the manuscript (from the start of the 
Introduction to the end of the Conclusion). The title page, contributors' statement page, 
abstract, acknowledgments, references, figures, tables, and multimedia are not included. 
Figures, Tables, and Supplementary Material 
For any figure, table, or supplementary material reproduced or adapted from another 
source, authors are required to obtain permission from the copyright holder, and proof of 
permission must be uploaded at the time of submission. The legend must include a 
statement that the material was used or adapted with permission. 
Figures 
Authors should number figures in the order in which they appear in the text. Figures 
include graphs, charts, photographs, and illustrations. Each figure must include a legend 
(placed as a list appearing after the References) that does not exceed 50 words. 
Abbreviations previously expanded in the text are acceptable. 
Figure arrays should be clearly labelled, preassembled, and submitted to scale. Figure 
parts of an array (A, B, C, etc.) should be clearly marked in capital letters in the upper left-
hand corner of each figure part. 
Technical requirements for figures: Upload figures as separate files; do not paste them in 
the manuscript text file. The following file types are acceptable: TIFF, PDF, EPS, and PNG. 
Colour files must be in CMYK (cyan, magenta, yellow, black) mode. Paediatrics cannot 
accept Excel or PowerPoint files for any part of your submission. There is no maximum 
number for figures. 
Style for figures: Readers should be able to understand figures without referring to the text. 
Avoid pie charts, 3-dimensional graphs, and excess ink in general. Make sure that the axes 
on graphs are labelled, including units of measurement, and that the font is large enough to 
read. Generally delete legends or other material from the graph if it makes the picture 
smaller. Colour graphs should be interpretable if photocopied in black and white. 
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There is no maximum number for figures or tables. 
Tables 
Tables should be numbered in the order in which they are cited in the text and include 
appropriate headers. Tables should not reiterate information presented in the Results 
section, but rather should provide clear and concise data that further illustrate the main 
point. Tabular data should directly relate to the hypothesis. Table formatting should follow 
the current edition of the AMA Manual of Style. There is no maximum number of tables. 
Technical requirements for tables: Tables should be constructed using a Microsoft Word 
program and inserted in numerical order at the end of the manuscript, either within the main 
Word document (following the references) or as separate files. Do not provide tables in 
scan/image format. Paediatrics cannot accept Excel or PowerPoint files for any part of your 
submission. There is no maximum number for tables. 
Style for tables: Tables should be self-explanatory. Avoid abbreviations; define any 
abbreviations in footnotes to the table. Avoid excess digits and excess ink in general. 
Where possible, rows should be in a meaningful order (e.g., descending order of 
frequency). Provide units of measurement for all numbers. In general, only one type of data 
should be in each column of the table. 
Presentation of Numbers and Statistics 
• Results in the abstract and the paper generally should include estimates of effect
size and 95% confidence intervals, not just P- values or statements that a
difference was statistically significant.
• Statistical methods for obtaining all P-values should be provided
• Units of independent variables must be provided in tables and results sections if
regression coefficients are provided
• Authors should avoid expressing effect sizes in the form of highly derived statistics.
Equations should be typed exactly as they are to appear in the final manuscript. The 
following table, adapted from the guidelines for authors for the Annals of Internal Medicine 
by editors of Medical Decision Making, shows how to present certain percentages and 
some statistical measures: 
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Reporting: Details: 
Percentages Report percentages to one decimal place (i.e., xx.x%) when sample 
size is greater than or equal to 200. 
To avoid the appearance of a level of precision that is not present with small 
samples, do not use decimal places (i.e., xx%, not xx.x%) when sample size 
is less than 200. 
Error 
Meas
ures 
Report confidence intervals, rather than standard errors, when possible. Use 
"mean (error measures)" rather than "mean ± error measure" notation. 
P 
value
s 
―Tren
d
Except when one-sided tests are required by study design, such as in 
noninferiority trials, all reported P values 
Should be two-sided. In general, P values larger than 0.01 should be reported 
to two decimal places, those between 
0.01 and 0.001 to three decimal places; P values smaller than 0.001 should be 
reported as P [is less than sign] 
0.001. Notable exceptions to this policy include P values arising in the 
application of stopping rules to the analysis 
Of clinical trials and genetic-screening studies. 
Use the word trend when describing a test for trend or dose-response 
Avoid the term "trend" when referring to p-values near but not 
below 0.05. In such instances, simply report a difference and 
the confidence interval of the difference (if appropriate) with or 
without the p-value.
Supplemental Information 
Authors may wish to include additional information as part of their article for inclusion in 
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the online edition of Paediatrics. References to any online supplemental information 
must appear in the main article. Such supplemental information can include but are not 
limited to additional tables, figures, videos, audio files, slide shows, data sets (including 
qualitative data), and online appendices. If your study is based on a survey, consider 
submitting your survey instrument or the key questions as a data supplement. Authors 
are responsible for clearly labelling supplemental information and are accountable for its 
accuracy. Supplemental information will be peer reviewed, but not professionally 
copyedited. 
Videos 
Paediatrics encourages the submission of videos to accompany articles where 
relevant. Links can be placed in the article for use when it is accessed electronically. 
All videos must adhere to the same general permission rules that apply to figures 
(i.e.: parental consent when a patient is identifiable). 
All videos should be submitted at the desired reproduction size and length. To avoid 
excessive delays in downloading the files, videos should be no more than 6MB in size, 
and run between 30 and 60 seconds in length. In addition, cropping frames and image 
sizes can significantly reduce file sizes. Files submitted can be looped to play more than 
once, provided file size does not become excessive. Video format must be either .mov 
or .mp4. 
Authors will be notified if problems exist with videos as submitted, and will be asked to 
modify them if needed. No editing will be done to the videos at the editorial office—all 
changes are the responsibility of the author. 
Video files should be named clearly to correspond with the figure they represent (i.e., 
figure1.mov, figure2.mp4, etc.). Be sure all video files have filenames that are no more 
than 8 characters long and include the suffix ―.mov‖ or ".mp4." A caption for each video 
should be provided (preferably in a similarly named Word file submitted with the 
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videos), stating clearly the content of the video presentation and its relevance to the 
materials submitted. 
IMPORTANT: One to four traditional still images from the video must be provided. 
These still images may be published with the article and will act as thumbnail images 
in the electronic edition that will link to the full video file. Please indicate clearly in your 
text whether a figure has a video associated with it, and be sure to indicate the name 
of the corresponding video file. A brief figure legend should also be provided. 
Regular Article 
Abstract length: 250 words or fewer (structured, as noted below) 
Article length: 3,000 words or fewer 
Regular Articles are original research contributions that aim to inform clinical practice 
or the understanding of a disease process. Regular Articles include but are not limited 
to clinical trials, interventional studies, cohort studies, case-control studies, 
epidemiologic assessments, and surveys. Components of a Regular Article include: 
• What‘s Known on This Subject
• What This Study Adds
These two brief summaries are each limited to 40 words. Please use precise and 
accurate language in paragraph form (i.e., not bullet points). For manuscripts accepted 
as Regular Articles, these summaries will become a highly visible part of your published 
paper, with prominence on the first page. Moreover, these summaries may be 
highlighted and presented in other areas of the journal. It is therefore paramount that 
you use language of the same calibre as the rest of your paper. 
• Structured Abstract (four paragraphs with headings in boldface type; single-spaced)
The abstract should consist of: Background (or Objectives, or Background and 
Objectives), Methods, Results, and Conclusions. The Objective should clearly state the 
hypothesis; Methods, inclusion criteria and study design; Results, the outcome of the 
study; and Conclusions, the outcome in relation to the hypothesis and possible 
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directions of future study. 
• Body of Article
For the body of your article, follow this general outline: 
• Introduction
A 1- to 2-paragraph introduction outlining the wider context that generated the study and 
the hypothesis. 
• Patients and Methods
This section should detail inclusion criteria and study design to ensure reproducibility 
of the research. All studies that involve human subjects must be approved or 
deemed exempt by an official institutional review board; this should be noted here. 
• Results
This section should give specific answers to the aims or questions stated in the 
introduction. The order of presentation of results should parallel the order of the 
methods section. 
• Discussion
The section should highlight antecedent literature on the topic and how the current 
study changes the understanding of a disease process or clinical situation, and should 
include a section on the limitations of the present study. 
• Conclusion
A brief concluding paragraph presenting the implications of the study results and 
possible new research directions on the subject. 
General submission instructions (including cover letter, title page requirements, 
contributors' statement page, journal style guidance, and conflict of interest statements) 
apply to Regular Articles 
